| Title |
ROW |
| 2019 Novel coronavirus infection and gastrointestinal tract |
1 |
| 2019 Novel Coronavirus—Important Information |
2 |
| 2019_nCoVRapid classification of betacoronaviruses and identification of traditional |
3 |
| 2019-nCoV epidemic what about pregnancies |
4 |
| 2019-nCoV in context lessons learned |
5 |
| 2019-novel Coronavirus severe adult respiratory distress |
6 |
| 2019-novel-coronavirus--2019-nCoV--outbrea_2020_Journal-of-Global-Antimicrob |
7 |
| 2019-novel-coronavirus-disease--COVID-19--in-T_2020_Journal-of-Microbiology- |
8 |
| A case of 2019 Novel Coronavirus in a pregnant woman with preterm delivery |
9 |
| A conceptual model for the coronavirus disease 2019 (COVID-19) |
10 |
| A conceptual model for the outbreak of Coronavirus disease 2019 (COVID-19) in Wuhan, China with individual reactio-OCM_K8DT |
11 |
| A distinct name is needed for the new coronavirus |
12 |
| A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmissio-BXUMJ4IU |
13 |
| A Genomic Perspective on the Origin |
14 |
| A Locally Transmitted Case of SARS-CoV-2 Infection in Taiwan |
15 |
| A mild type of childhood Covid-19 - A case report |
16 |
| A new pandemic out of China the Wuhan 2019-nCoV coronavirus |
17 |
| A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome |
18 |
| A Novel Coronavirus Emerging in China Key Questions for Impact Assessment |
19 |
| A Novel Coronavirus from Patients with |
20 |
| A novel coronavirus outbreak of global health concern |
21 |
| A Novel Coronavirus(COVID-19) Outbreak A Call for Action |
22 |
| A novel presentation of COVID-19 via community acquired infection |
23 |
| A pneumonia outbreak associated with a new coronavirus of probable bat origin |
24 |
| A potential role for integrins in host cell entry by SARS-CoV-2 |
25 |
| A Promising Anti-Cytokine-Storm Targeted Therapy for COVID-19 The |
26 |
| A risk-based approach is best for decision making on holding mass gathering events |
27 |
| A segregated-team model to maintain cancer care during the COVID-19 outbreak at |
28 |
| A Sequence Homology and Bioinformatic Approach |
29 |
| A special case of COVID-19 with long duration of viral shedding for 49 days |
30 |
| A strategy to prevent future epidemics similar to the 2019-nCoV outbreak |
31 |
| A-case-of-COVID-19-and-pneumonia-returning-from-M_2020_Journal-of-Microbiolo |
32 |
| Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19) |
33 |
| Actualización de la situaciónepidemiológica de la infección porSARS-CoV-2 en Espa˜na. |
34 |
| ACUTE KIDNEY INJURY ASSOCIATED WITH |
35 |
| Adaptations de la prise en charge des patients en Nutrition Artificielle à Domicile au cours |
36 |
| Advance of promising target sagainst Q1 |
37 |
| Advice on Standardized Diagnosis and Treatment for Spinal Diseases during the Coronavirus Disease 2019 Pandemic |
38 |
| Aetiology of lower respiratory tract infection in adults in primary care a prospective study in 11 European countries |
39 |
| Africa prepares for coronavirus |
40 |
| Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome C-9AO8OJFO |
41 |
| Aminoquinolines against coronavirus disease 2019 (COVID-19) |
42 |
| An update on the 2019-nCoV outbreak |
43 |
| An updated estimation of the risk of transmission of the novel |
44 |
| Analysis and forecast of COVID-19 spreading in China, Italy and France |
45 |
| ANALYSIS Nearly every persondying from the coronavirus likely has these three things in common |
46 |
| Analysis of angiotensin-converting enzyme 2 (ACE2) from |
47 |
| Analysis of preferred codon usage in the coronavirus N genes and their |
48 |
| Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by |
49 |
| And now for something completely different from |
50 |
| Anesthetic Management of Patients Undergoing Aortic Dissection Repair With Suspected Severe Acute Respiratory Synd-63KLPUJD |
51 |
| Anesthetic-Management-of-Patients-with-COVID-_2020_Journal-of-Cardiothoracic |
52 |
| Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor molecular mechanisms and potential therapeutic target |
53 |
| Another coronavirus, another epidemic, another warning |
54 |
| Antigenic variation among recent Japanese isolates of bovine |
55 |
| Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 |
56 |
| Antipsoriatic treatments covid 19 |
57 |
| Application of the ARIMA model on the COVID- |
58 |
| Applying lessons from SARS to a newly identifi ed coronavirus |
59 |
| Approaches to the management of patients in oral and maxillofacial surgery during |
60 |
| Arbidol combined with LPVr versus LPVr alone against Corona Virus Disease 2019 A retrospective cohort study |
61 |
| Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection |
62 |
| A-review-of-the-2019-Novel-Coronavirus--COVI_2020_International-Journal-of-A |
63 |
| Arguments in favour of remdesivir for treating SARS-CoV-2 infections |
64 |
| Arthralgia as an initial presentation of COVID‑19- observation |
65 |
| Assessment of the SARS-CoV-2 basic |
66 |
| Association between ambient temperature and COVID-19 |
67 |
| Assurer les soins aux patients souffrant de troubles psychiques en |
68 |
| Asymptomatic novel coronavirus pneumonia patient outside Wuhan |
69 |
| Asymptomatic-carrier-state--acute-respiratory-disease-_2020_Journal-of-Micro |
70 |
| Asymptomatic-coronavirus-infection--MERS-CoV-a_2020_Travel-Medicine-and-Infe |
71 |
| A-systematic-review-on-the-efficacy-and-safety-of-chloro_2020_Journal-of-Cri |
72 |
| b68 Consecutive patients assessed for COVID-19 infection; experience from a UK regional infectious disease unit |
73 |
| Baricitinib for COVID-19- a suitable treatment |
74 |
| Base protocol for real time active random surveillance of |
75 |
| Breakthrough, Chloroquine phosphate has shown apparent |
76 |
| Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses |
77 |
| Building resilience against biological hazards and pandemics COVID-19 and |
78 |
| C0031_Specialty-guide_LD-and-coronavirus-v1_-24-March (1) |
79 |
| C0032-Maintenance-of-TB-services_26-March-FINAL (1) |
80 |
| C033-Specialty-guide_-Stroke-and-coronavirus-v1-24March_ (1) |
81 |
| C0063-Specialty-guide-_Respiratory-and-Coronavirus-_v1_26-March (1) |
82 |
| C0081-Speciality-guide-Palliative-care-and-coronavirus (1) |
83 |
| C0086_Specialty-guide-_Fragility-Fractures-and-Coronavirus-v1-26-March (1) |
84 |
| C0086_Specialty-guide_-Paediatric-critical-care-v1-26-March (1) |
85 |
| C0087-specialty-guide-critical-care-standard-operating-procedure-and-coronavirus-v1-28-march |
86 |
| C0099-specialty-guide-immunoglobulin-coronavirus-v1-31-march (1) |
87 |
| Can Bioactive Lipids Inactivate Coronavirus (COVID-19) |
88 |
| Can we contain the COVID-19 outbreak with the same measures as for SARS |
89 |
| Canada needs to rapidly escalate public health interventions for its COVID-19 |
90 |
| Cancer patients in SARS-CoV-2 infection a nationwide |
91 |
| Canwe contain the COVID-19 outbreak with the same |
92 |
| Cardiac troponin I in patients with coronavirus |
93 |
| Cardiovascular disease and COVID-19 |
94 |
| Cardiovascular-Considerations-for-Patients--Health-Ca_2020_Journal-of-the-Am |
95 |
| Caring for persons in detention suffering with mental illness during the |
96 |
| CARTA CIENTÍFICAPrimer caso de infección neonatalpor SARS-CoV-2 |
97 |
| Case of Novel Coronavirus Disease 19 in a Chronic Hemodialysis Patient Presenting with Gastroenteritis and Develop-9IS26O1D |
98 |
| Case of the Index Patient Who Caused |
99 |
| Caution and clarity required in the use of chloroquine for COVID-19 |
100 |
| CDC Director Says 1 In 4 May Have No Coronavirus Symptoms _ Shots - Health News |
101 |
| CD-sACE2 inclusion compound An effective treatment for corona virus disease 2019 COVID |
102 |
| Challenges and countermeasures for organ |
103 |
| Challenges of coronavirus disease 2019 |
104 |
| Challenges-of-SARS-CoV-2-and-lessons-learnt-from-SARS_2020_Journal-of-Clinic |
105 |
| Characteristics of and Important Lessons From |
106 |
| Characteristics of COVID-19 infection in Beijing |
107 |
| Characterization of novel monoclonal antibodies against MERS- |
108 |
| Chest CT for Non-Radiologists- A Practical Guide-2018 |
109 |
| Chest CT for Typical 2019-nCoV Pneumonia Relationship to Negative RT-PCR |
110 |
| China coronavirus cases surge as official admits |
111 |
| China coronavirus Hong Kong health staff strike to |
112 |
| China coronavirus mild but infectious cases may make |
113 |
| China coronavirus partial border closures into Hong |
114 |
| China coronavirus should be on “everybody’s agenda,” |
115 |
| China coronavirus what do we know so far |
116 |
| China coronavirus WHO declares international |
117 |
| China empowers Internet hospital to fight against COVID-19 |
118 |
| Chinese experts’ consensus on the Internet of Things-aided diagnosis and |
119 |
| Chinese Health Care Workers and COVID-19 For Whom the Bell Tolls |
120 |
| Chinese premier rallies medics in coronavirus fight |
121 |
| Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 |
122 |
| Chloroquine and hydroxychloroquine as available weapons to fight |
123 |
| Chloroquine-and-hydroxychloroquine-in-the-treatment-of-_2020_Diabetes---Meta |
124 |
| Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID‑19) infection |
125 |
| Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 |
126 |
| CIENTÍFICAPrimer caso de infección neonatalpor SARS-CoV-2 en Espa˜na |
127 |
| CLEARED_Specialty-guide_-NIV-respiratory-support-and-coronavirus-v2-26-March-003 (1) |
128 |
| Clinical and CT features in pediatric patients with COVID-19 infection, Different points from adults |
129 |
| Clinical and CT imaging features of 2019 novel coronavirus disease (COVID-19) |
130 |
| Clinical and CT imaging features of the COVID-19 pneumonia Focus |
131 |
| Clinical and epidemiological features of 36 children with |
132 |
| Clinical and High-Resolution CT Features of the COVID-19 Infection, Comparison of the Initial and Follow-up Changes |
133 |
| Clinical and virological data of the first cases of COVID-19 |
134 |
| Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19)A multi-center-R2_O8L7J |
135 |
| Clinical characteristics and intrauterine vertical transmission |
136 |
| Clinical characteristics and therapeutic procedure for four cases |
137 |
| Clinical Characteristics of 138 Hospitalized Patients |
138 |
| Clinical Characteristics of Coronavirus |
139 |
| Clinical characteristics of COVID-19-infected cancer patients A retrospective case |
140 |
| Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province A Multicenter Descriptive Study |
141 |
| Clinical characteristics of laboratory confirmed positive cases of SARS-CoV- |
142 |
| clinical characteristics of medical staff in covid 19 |
143 |
| Clinical characteristics of novel coronavirus |
144 |
| Clinical considerations for patients with diabetes in times of COVID-19 |
145 |
| Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China a single-centere-R6XSVQPJ |
146 |
| Clinical course and risk factors for mortality of adult |
147 |
| Clinical evidence does not support corticosteroid treatment |
148 |
| Clinical features and obstetric and neonatal outcomes |
149 |
| Clinical features and short-term outcomes |
150 |
| Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus -AOEO83FO |
151 |
| Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection |
152 |
| Clinical features of COVID-19 in elderly patients A comparison with young and middle-aged patients |
153 |
| Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China |
154 |
| Clinical findings in a group of patients infected with the 2019 |
155 |
| Clinical guide for the management of major trauma patients during the coronavirus pandemic |
156 |
| Clinical Overview_Coronavirus novel coronavirus (COVID-19) |
157 |
| Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China |
158 |
| Clinical progression of patients with COVID-19 in Shanghai, China |
159 |
| Clinical Study of Mesenchymal Stem Cell Treatment for Acute |
160 |
| Clinical trial analysis of 2019-nCoV therapy |
161 |
| Clinical, laboratory and imaging features of COVID-19 A systematic review |
162 |
| Clinical-and-computed-tomographic-imaging-features-of-novel_2020_Journal-of- |
163 |
| Clinical-characteristics-of-severe-acute-respiratory-syndr_2020_Journal-of-I |
164 |
| Clinical-features-of-cases-and-a-cluster-of-Coronaviru_2020_Travel-Medicine- |
165 |
| clinical-guide-for-staff-supporting-patients-with-a-learning-disability-autism-or-both-easy-read |
166 |
| clinical-guide-rheumatology-patients-v1-19-march-2020-updated (1) |
167 |
| clinical-management-of-persons-admitted-to-hospita-v1-19-march-2020 |
168 |
| CO0043_Specialty-guide-and-coronavirus_-MSK-corcosteroid_-v1-25March (1) |
169 |
| Combination of RT-qPCR Tes t ing and Clinical Features For |
170 |
| Commentary Of chloroquine and COVID-19 |
171 |
| Comments on P¨ reliminary estimation of the basic reproduction number of novel Coronavirus |
172 |
| Community pharmacist in public health emergencies Quick to action |
173 |
| Community pharmacists and communication in the time of COVID-19 |
174 |
| Comparison of different samples for 2019 novel coronavirus |
175 |
| Comparison of Hospitalized Patients with Acute Respiratory Distress Syndrome |
176 |
| Comparison-of-clinical-characteristics-of-coronavirus-di_2020_Travel-Medicin |
177 |
| Composition-of-human-specific-slow-codons-and-slow-di-co_2020_Journal-of-Mic |
178 |
| Computers-and-viral-diseases--Preliminary-bioinformatics-stud_2020_Computers |
179 |
| Considerations in performing endoscopy during the COVID-19 pandemic |
180 |
| Contentious issues and evolving concepts in the clinical presentation |
181 |
| Continuous evolution of avian infectious bronchitis virus resulting in different variants co-circulating in southern China |
182 |
| Core Outcome Set for Clinical Trials on Coronavirus Disease 2019 |
183 |
| Corona Virus Disease 2019, a growing threat to children |
184 |
| Corona Virus International Public Health Emergencies Implications for Radiology Management |
185 |
| corona virus |
186 |
| Coronavirus (COVID-19) Outbreak What the Department of Radiology Should Know |
187 |
| Coronavirus 2019-nCoV Is the genie already out of the bottle |
188 |
| Coronavirus can infect cats — dogs, not so much |
189 |
| Coronavirus Disease (COVID-19) Spectrum of CT Findings and Temporal Progression of the Disease |
190 |
| Coronavirus disease 2019 (COVID-19)- facts and controversies |
191 |
| Coronavirus Disease 2019 (COVID-19) Pneumonia |
192 |
| Coronavirus Disease 2019 (COVID-19), A Perspective from China |
193 |
| Coronavirus disease 2019 (COVID-19) |
194 |
| Coronavirus Disease 2019 and Influenza |
195 |
| Coronavirus Disease COVID-19, A New Threat to Public Health |
196 |
| Coronavirus doctor who faced backlash from police |
197 |
| Coronavirus does spread through the air and lingers in rooms long after patients have left |
198 |
| Coronavirus global stocks of protective gear are |
199 |
| Coronavirus in mother and baby |
200 |
| Coronavirus infections reported by ProMED, February 2000–January 2020 |
201 |
| Coronavirus latest pandemic could have killed 40 million without any action |
202 |
| Coronavirus masks advice could change after new evidence emerges |
203 |
| Coronavirus online GP bookings should be stopped |
204 |
| Coronavirus- Potential vaccine generates enough antibodies to fight off virus, first peer-reviewed study suggests |
205 |
| Coronavirus- Scientists in Australia begin testing two potential vaccines |
206 |
| Coronavirus shows how UK must act quickly before |
207 |
| Coronavirus UK screens direct flights from Wuhan |
208 |
| Coronavirus-2019-nCoV--A-brief-perspective-from-the-f_2020_Journal-of-Infect |
209 |
| Coronavirus-Disease-2019--Coronaviruses-and-Blo_2020_Transfusion-Medicine-Re |
210 |
| Coronavirus-Disease-2019--COVID-19--and-Pregna_2020_American-Journal-of-Obst |
211 |
| Coronavirus-disease-2019--COVID-19---current_2020_International-Journal-of-A |
212 |
| Coronavirus-Disease-2019--COVID-19--Pand_2020_American-Journal-of-Obstetrics |
213 |
| Coronavirus-Disease--COVID-19---A-primer-fo_2020_The-American-Journal-of-Eme |
214 |
| Coronaviruses in animals and humans |
215 |
| Coronaviruses |
216 |
| Covid 19 epidemic disease Characteritics in children |
217 |
| COVID 19 in INDIA Strategies to combat from |
218 |
| COVID-19 - Face Masks and Human-to-human Transmission |
219 |
| Covid-19 — Navigating the Uncharted |
220 |
| COVID-19 – the role of mass gatherings |
221 |
| COVID-19 A critical care perspective informed by lessons learnt from |
222 |
| COVID-19 a novel coronavirus and a novel |
223 |
| Covid-19 a puzzle with many missing pieces |
224 |
| COVID-19 and Blood Safety Help with a Dilemma |
225 |
| COVID-19 and diabetes Can DPP4 inhibition play a |
226 |
| COVID-19 and ImmunomodulatorImmunosuppressant Use in Dermatology |
227 |
| COVID-19 and Italy what next |
228 |
| COVID-19 and the anti-lessons of history |
229 |
| Covid-19- BSTIBSGAR decision tool for chest imaging in patients undergoing CT for acute surgical abdomen |
230 |
| COVID-19 Challenges to GIS with Big Data |
231 |
| COVID-19- combining antiviral and anti-inflammatory treatments |
232 |
| COVID-19 Computed Tomography Findings A Systematic Review and Meta-Analysis |
233 |
| COVID-19 consider cytokine storm syndromes and immunosuppression |
234 |
| COVID-19 Gastrointestinal Manifestations and Potential Fecal–Oral Transmission |
235 |
| COVID-19 Global radiation oncology’s targeted response for pandemic |
236 |
| COVID-19 HOW CAN A DEPARTMENT OF GENERAL SURGERY SURVIVE TO A |
237 |
| COVID-19 in children More than meets the eye |
238 |
| COVID-19 in children the link in the transmission chain |
239 |
| COVID-19 in Hemodialysis Patients A Report of 5 Cases |
240 |
| COVID-19 in Kidney Transplant Recipients |
241 |
| COVID-19 in Latin America The implications of the first confirmed case in Brazil |
242 |
| COVID-19 in patients with cardiovascular |
243 |
| COVID-19 in Singapore—Current Experience |
244 |
| COVID-19 Infection in a Patient with End-Stage Kidney Disease |
245 |
| COVID-19 Lessons from SARS and MERS |
246 |
| COVID-19 Melatonin as a Potential Adjuvant Treatment |
247 |
| COVID-19 Pandemic Staged Management of Surgical Services for Gynecology and |
248 |
| COVID-19 Personal Protective Equipment (PPE) for the emergency |
249 |
| COVID-19 pneumonia what has CT taught us |
250 |
| Covid-19 preparedness, decentralisation, and the hunt |
251 |
| COVID-19 preparing for superspreader potential among Umrah pilgrims to Saudi Arabia |
252 |
| Covid-19 school closures and bans on mass |
253 |
| COVID-19 spike-host cell receptor GRP78 binding site prediction |
254 |
| Covid-19 surge in cases in Italy and South Korea |
255 |
| COVID-19 therapeutic options for patients with Kidney Disease |
256 |
| COVID-19 through the lens of gerontology |
257 |
| Covid-19 Trump says risk to Americans is “very low” |
258 |
| COVID-19 Yet another coronavirus challenge in |
259 |
| COVID-19 Zoonotic aspects |
260 |
| COVID–19, Journal de bord–18022020– |
261 |
| COVID-19, the gendered impacts of the outbreak |
262 |
| COVID-19, una emergencia de salud pública mundial |
263 |
| COVID-19__lung_cancer_pathway_guidance_final |
264 |
| COVID-19--Epidemiology--Evolution--and-Cross-Disci_2020_Trends-in-Molecular- |
265 |
| COVID-19-infection-and-rheumatoid-arthritis--Faraway--_2020_Autoimmunity-Rev |
266 |
| COVID-19-infection--Origin--transmission--and-charact_2020_Journal-of-Advanc |
267 |
| COVID-19—New Insights on a Rapidly Changing Epidemic |
268 |
| COVID-19--SARS-and-MERS--are-they-closely-_2020_Clinical-Microbiology-and-In |
269 |
| covid-19-testing-and-staff-retention-letter-29-march-2020 (1) |
270 |
| COVID-2019 the role of the nsp2 and nsp3 in its pathogenesis |
271 |
| Critical care crisis and some |
272 |
| Critical care management of adults |
273 |
| Current knowledge about the antivirals remdesivir (GS-5734) and GS- |
274 |
| Defining the Epidemiology of Covid-19 — Studies Needed |
275 |
| Dental journals and coronavirus disease (COVID-19) A current view |
276 |
| Dermatirtis and Covid 19 |
277 |
| Detection of SARS-CoV-2 in Different Types of Clinical Specimens |
278 |
| Developing antibody tests for SARS-CoV-2 |
279 |
| Developing Covid-19 Vaccines at Pandemic Speed |
280 |
| Development and Clinical Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis |
281 |
| Development of epitope-based peptide vaccine against novel |
282 |
| Development of protection against coronavirus induced diseases. A review |
283 |
| Diabetes is a risk factor for the progression and prognosis of COVID-19 |
284 |
| Diagnosis of SARS-CoV-2 Infection based on CT scan vs. RT-PCR, Reflecting on Experience from MERS-CoV |
285 |
| Diagnosis of severe respiratory infections |
286 |
| Diagnosis of the Coronavirus disease (COVID-19) rRT-PCR or CT |
287 |
| Diagnostic-value-and-dynamic-variance-of-serum_2020_International-Journal-of |
288 |
| DisinfectionChamber finalized |
289 |
| Do children need a longer time to shed SARS- |
290 |
| Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection |
291 |
| Duration of quarantine in hospitalized patients with severe acute respiratory syndromecoronavirus 2 (SARS-CoV-2) i-2GFNCU3W |
292 |
| Duration of serum neutralizing antibodies for |
293 |
| Duration-of-quarantine-in-hospitalized-patients-with-severe_2020_Journal-of- |
294 |
| Dynamic-change-process-of-target-genes-by-RT-PCR-testing-of-S_2020_Clinica-C |
295 |
| Early epidemiological analysis of the coronavirus disease |
296 |
| Early Transmission Dynamics in Wuhan, China, |
297 |
| Early-dynamics-of-transmission-and-control-of-COVID-_2020_The-Lancet-Infecti |
298 |
| EASL-ESCMID-Position-Paper-on-COVID-19-and-the-liver-2-April-2020 |
299 |
| Economic Impacts of Wuhan 2019-nCoV on China and the |
300 |
| COVID-19: Use Regional Anesthesia Wherever Possible |
301 |
| Effective Chemicals against Novel Coronavirus (COVID-19) in China |
302 |
| Effective strategies to prevent coronavirus disease-2019 (COVID-19) outbreak in hospital |
303 |
| Effects of progressive muscle relaxation on anxiety and sleep quality in |
304 |
| Effects of temperature variation and humidity on the death of |
305 |
| Effects of the COVID-19 Outbreak in Northern Italy Perspectives from the Bergamo |
306 |
| Emergence of a novel coronavirus causing respiratory |
307 |
| Emergency management of nursing human resources and supplies to respond to |
308 |
| Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV |
309 |
| Enhancing Private Sector Health System Preparedness |
310 |
| Ensuring global access to COVID-19 vaccines |
311 |
| Enteric involvement of coronaviruses is faecal–oral |
312 |
| Enteropathogen co-infection in UK cats with diarrhoea |
313 |
| Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China |
314 |
| Epidemiologic Features and Clinical Course of Patients Infected |
315 |
| Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, |
316 |
| Epidemiological characteristics and transmission model of |
317 |
| Epidemiological, clinical characteristics of cases of SARS-CoV-2 |
318 |
| Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronav-BLDUHJAH |
319 |
| Epidemiology, genome, and clinical features of the pandemic SARSCoV-2 a recent |
320 |
| Escaping Pandora’s Box — Another Novel Coronavirus |
321 |
| Espen expert statements and practical guidance for nutritional management of |
322 |
| Essential care of critical illness must not be forgotten in the COVID-19 pandemic |
323 |
| Estimates of the severity of coronavirus disease 2019- a model-based analysis |
324 |
| Estimating case fatality rates of COVID-19 |
325 |
| Estimating the number of infections and the impact of nonpharmaceutical interventions on COVID-19 in 11 European countries |
326 |
| Estimation of the reproductive number of novel coronavirus |
327 |
| Estimation of the Transmission Risk of the 2019‐nCoV and Its Implication forPublic Health Interventions |
328 |
| Ethical Outpatient Dermatology Care During the Coronavirus (COVID-19) Pandemic |
329 |
| Evaluation of the Effectiveness of Surveillance and Containment Measures for theFirst 100 Patients with COVID-19 i-N7FA529S |
330 |
| |
331 |
| Evidence of SARS-CoV-2 Infection in Returning |
332 |
| Evolving epidemiology and transmission dynamics of |
333 |
| Evolving reporting criteria of COVID-19 in |
334 |
| Evolving status of the 2019 novel coronavirus Infection proposal |
335 |
| Excitement around hydroxychloroquine for treating COVID-19 causes challenges for rheumatology |
336 |
| Experience and suggestion of medical practices for burns during the |
337 |
| Experience-on-radiological-examinations-and-infection-_2020_Radiology-of-Inf |
338 |
| Exploring the reasons for healthcare workers infected with novel coronavirus disease 2019 (COVID-19) in China |
339 |
| Extracorporeal membrane oxygenation (ECMO) does it have a role in the |
340 |
| Facemaskshortageandthenovelcoronavirusdisease(COVID-19)outbreakReflectionsonpublichealthmeasures |
341 |
| Facing the COVID-19 outbreak What should we know and |
342 |
| Factsheet13.10.01-Fa-Final PDF |
343 |
| favipiravir-for-covid-19-(26-march-2020) |
344 |
| FDA authorizes emergency use of unapproved drugs to treat coronavirus - The Wash |
345 |
| Feasibility of controlling COVID-19 outbreaks by isolation of |
346 |
| Featuring-COVID-19-cases-via-screening-symptomatic-p_2020_Journal-of-Microbi |
347 |
| First Case of 2019 Novel Coronavirus in the United States |
348 |
| First case of Coronavirus Disease 2019 |
349 |
| First imported case of 2019 novel coronavirus in Canada, presenting as mild pneumonia |
350 |
| First respiratory transmitted food borne outbreak |
351 |
| First-known-person-to-person-transmission-of-severe-acute-respira_2020_The-L |
352 |
| From Bats to Human Lungs the Evolution of a Coronavirus The New Yorker |
353 |
| From-SARS-to-COVID-19--A-previously-unknown-SARS--related-coronavi_2020_One- |
354 |
| Full genome analysis of a novel type II feline coronavirus NTU156 |
355 |
| Full-genome-evolutionary-analysis-of-the-novel-corona-viru_2020_Infection--G |
356 |
| Game consumption and the 2019 novel coronavirus |
357 |
| Gastrointestinal features of covid 19 |
358 |
| Genetic and Molecular Biological Analysis of Protein-Protein Interactions in Coronavirus Assembly |
359 |
| Genetic diversity and evolution of SARS-CoV-2 |
360 |
| Genetic-evolution-analysis-of-2019-novel-coronaviru_2020_Infection--Genetics |
361 |
| Genome-Composition-and-Divergence-of-the-Novel-Coronavirus_2020_Cell-Host--- |
362 |
| Genomic characterisation and epidemiology of 2019 novel |
363 |
| GENOMIC CHARACTERISATION AND PHYLOGENETIC ANALYSIS OF SARS-COV-2 IN ITALY |
364 |
| Genotype-and-phenotype-of-COVID-19--Thei_2020_Journal-of-Microbiology--Immun |
365 |
| Global coalition to accelerate COVID-19 clinical research in |
366 |
| Global epidemiology of coronavirus disease 2019 (COVID-19) disease incidence, daily cumulative index, mortality, a-5Q46QUF9 |
367 |
| Going global – Travel and the 2019 novel coronavirus |
368 |
| Guidance for the management of myasthenia gravis (MG) and Lambert- |
369 |
| Guidance_for_Triage_of_Nonemergent_Surgical_Procedurespdf |
370 |
| Guidelines for pregnant women with suspected SARS-CoV-2 infection |
371 |
| Guillain-Barré syndrome associated with SARS-CoV-2 infection- causality or coincidence |
372 |
| Handling the COVID-19 pandemic in the oncological setting |
373 |
| Has China faced only a herald wave of SARS-CoV-2 |
374 |
| Health security capacities in the context of COVID-19 |
375 |
| Healthcare impact of COVID-19 epidemic in India A stochastic mathematical model |
376 |
| Hepatic-and-gastrointestinal-involvement-in-coronaviru_2020_Arab-Journal-of- |
377 |
| High-resolution computed tomography manifestations of COVID-19 |
378 |
| Home care for cancer patients during COVID-19 pandemic the “double triage” |
379 |
| Homologous recombination within the spike glycoprotein |
380 |
| Hospital pharmacists’ pharmaceutical care for hospitalized patients with COVID-19 |
381 |
| How Chinas Bat Woman Hunted Down Viruses from SARS to the New Coronavirus - S |
382 |
| How sick will the coronavirus make you |
383 |
| How South Korea Flattened the Coronavirus Curve - The New York Times 1 |
384 |
| How to clean your home for coronavirus explained by an expert - Vox 1 |
385 |
| How to face the novel coronavirus infection |
386 |
| How to link patients with suspicious COVID-19 to health system from the |
387 |
| Human Respiratory Viral Infections-2014 |
388 |
| Hydroxychloroquine and azithromycin as a treatment of COVID-19 results of an openlabel |
389 |
| Identification and genetic characterization of porcine hemagglutinating encephalomyelitis virus from domestic pigle-H-IQ7IJW |
390 |
| Identification of 60-b-fluoro-homoaristeromycin as a potent inhibitor |
391 |
| Identification of a Novel Coronavirus in Patients |
392 |
| Identification of Kidney Transplant Recipients with Coronavirus |
393 |
| Identification of potential cross-protective epitope between a new type |
394 |
| Identification of the hyper-variable genomic hotspot for the |
395 |
| Identifying-factors-and-target-preventive-therapies-for-_2020_Saudi-Pharmace |
396 |
| IDM editorial statement on the 2019-nCoV |
397 |
| Imaging changes in severe COVID-19 pneumonia |
398 |
| Imaging changes of severe COVID-19 pneumonia in advanced stage |
399 |
| Imaging Features of Coronavirus disease 2019 (COVID-19) Evaluation on Thin-Section CT |
400 |
| Imaging manifestations and diagnostic value of chest CT of coronavirus disease 2019 (COVID-19) in the Xiaogan area |
401 |
| Immunoinformatics-aided identification of T cell and B cell |
402 |
| Importation and Human-to-Human Transmission |
403 |
| Importing coronavirus disease 2019 (COVID-19) into China after |
404 |
| In Beijing, coronavirus 2019-nCoV has created a siege |
405 |
| In silico screening of Chinese herbal medicines with the potential to |
406 |
| Incidence-of-novel-coronavirus--2019-nCoV--infection_2020_Travel-Medicine-an |
407 |
| Infection à SARS-CoV-2COVID 19 et cancers solides synthèse des |
408 |
| Infection par le SARS-CoV-2 chez les femmes enceintes. E´ tat des |
409 |
| Infographic_ The History of Pandemics by Death Toll |
410 |
| Initial Public Health Response and Interim Clinical Guidance for |
411 |
| Insight-into-2019-novel-coronavirus---an-updated-_2020_International-Journal |
412 |
| Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks. |
413 |
| Instructions for controlling infection in anesthesia and surgery during coronavirus infection |
414 |
| Instructions for training to take care of yourself and others against COVID-19 in the office |
415 |
| Intensive care during the coronavirus |
416 |
| Interim Guidance for Healthcare Facilities Preparing for Community Transmission of COVID-19 in the United States |
417 |
| Internationally lost COVID-19 cases |
418 |
| Interpretation of the diagnosis and treatment plan of Corona Virus |
419 |
| Interrupting COVID-19 transmission by |
420 |
| Interventional Cardiology and Covid 19 |
421 |
| Interventions to mitigate early spread of SARS-CoV-2 |
422 |
| intranasal corticosteroids and covid19 |
423 |
| Intranasal vaccination with recombinant receptor-binding domain of |
424 |
| Investigation of three clusters of COVID-19 in Singapore |
425 |
| Is Africa prepared for tackling the COVID-19 (SARS-CoV-2) |
426 |
| Is COVID-19 receiving ADE from other coronaviruses |
427 |
| Is the Coronavirus Airborne Should We All Wear Masks - The Atlantic |
428 |
| Journal of the Epidemiological Analysis Committee |
429 |
| Journey of a Thai Taxi Driver and Novel Coronavirus |
430 |
| Keratoconjunctivitis as the initial medical presentation of the novel |
431 |
| Kidney disease is associated with in-hospital death of patients with COVID-19 |
432 |
| Labor and Delivery Guidance for COVID-19 |
433 |
| Lack of small animal model hinders MERS coronavirus research |
434 |
| Le nouveau Coronavirus Covid-19 quels |
435 |
| Learning from the Past Possible Urgent Prevention and |
436 |
| Lessons From Italys Hospital Meltdown Every Day You Lose the Contagion Gets |
437 |
| Lessons learned from the 2019-nCoV epidemic on prevention of future |
438 |
| Letter from China covid-19 on the grapevine, on the |
439 |
| letter to Jahanpour final version |
440 |
| Levofloxacin prophylaxis in patients with newly diagnosed |
441 |
| Li Wenliang, a face to the frontline healthcare worker. The first |
442 |
| Lianhuaqingwen-exerts-anti-viral-and-anti-inflammatory-ac_2020_Pharmacologic |
443 |
| Liver injury in COVID-19 management and challenges |
444 |
| Lopinavir-ritonavir-did-not-shorten-the-duration-_2020_Journal-of-Microbiolo |
445 |
| Lymphopenic community acquired pneumonia as signature of severe COVID-19 infection, Lymphopenia in severe COVID-19-C06H8WK5 |
446 |
| Maintaining a safe and adequate blood supply during the pandemic outbreak of coronavirus disease (COVID-19) |
447 |
| Management of Cardiac Surgical Patients with Suspected or |
448 |
| mask and hand hygine covid 19 |
449 |
| Measures for diagnosing and treating infections by a novel |
450 |
| Medical Education Adaptations Really Good Stuff for Educational Transition during a |
451 |
| Medical student involvement in the COVID-19 response |
452 |
| Medicine- before COVID-19, and after |
453 |
| MERS-CoV infection among healthcare workers and risk factors for |
454 |
| MERS-CoV infection is associated with downregulation of genes encoding |
455 |
| Message from the Editor- Stem Cell Science in the Time of COVID-19 |
456 |
| Microneedle array delivered recombinant coronavirus vaccines- Immunogenicity and rapid translational development |
457 |
| |
458 |
| Middle East Respiratory Syndrome (MERS) coronavirus. What travel health advice should be given to Hajj pilgrims |
459 |
| Middle East Respiratory Syndrome Coronavirus Another Zoonotic |
460 |
| Middle East respiratory syndrome coronavirus |
461 |
| Middle-East-respiratory-syndrome-coronavirus--MERS-_2020_International-Journ |
463 |
| Mitigate the effects of home confinement on children during the COVID-19 outbreak |
464 |
| Modeling the dynamics of novel coronavirus |
465 |
| Modelling COVID-19 transmission- from data to intervention |
466 |
| Molecular basis of COVID-19 relationships in different species a one |
467 |
| Molecular-immune-pathogenesis-and-diagnosis-_2020_Journal-of-Pharmaceutical- |
468 |
| Monitoring behavioural insights related to COVID-19 |
469 |
| Monitoring Transmissibility and Mortality of COVID-19 in Europe |
470 |
| N95 Respirators and Surgical Masks Blogs CDC |
471 |
| N95 Respirators vs Medical Masks for Preventing Influenza |
472 |
| Nafamostat is expected to prevent the transmission of new coronavirus infection (COVID-19) _ EurekAlert! Science News |
473 |
| Navigating the challenges of the COVID-19 outbreak perspectives from the |
474 |
| Nervous system involvement after infection with COVID-19 and other coronaviruses |
475 |
| Neuroinfection may potentially contribute to pathophysiology and clinical manifestations of COVID-19 |
476 |
| Neurosurgery during the COVID-19 pandemic- update from Lombardy, northern Italy |
477 |
| Neutralizing-Antibodies-against-SARS-CoV-2-and-Other-Hu_2020_Trends-in-Immun |
478 |
| New coronavirus with “pandemic potential” sparks global surveillance efforts |
479 |
| New therapeutic opportunities for COVID-19 patients with Tocilizumab Possible correlation of |
480 |
| New-insights-on-the-antiviral-effects-of-chloroqu_2020_International-Journal |
481 |
| newsletter of IPA_1399_1_50 |
482 |
| No time for dilemma- mass gatherings must be suspended |
483 |
| Nonstructural proteins NS7b and NS8 are likely to be phylogenetically associated with evolution of 2019-nCoV |
484 |
| Coronavirus disease 2019 (COVID-19): Epidemiology, virology, and prevention |
485 |
| Not wearing masks to protect against co.. |
486 |
| Novel and Re-emerging Respiratory Viral Diseases-2008 |
487 |
| Novel coronavirus From discovery to clinical diagnostics |
488 |
| Novel coronavirus 2019 (COVID-19) Emergence and |
489 |
| Novel coronavirus Australian GPs raise concerns |
490 |
| Novel Coronavirus disease 2019 (COVID-19) The importance of recognising possible early ocular manifestation and us-6T8U1697 |
491 |
| Novel coronavirus From discovery to clinical diagnostics |
492 |
| Novel coronavirus infection during the 2019–2020 epidemic preparing intensive care units—the experience in Sichuan-FXYIPBV5 |
493 |
| Novel Coronavirus Infection in Hospitalized Infants |
494 |
| Novel coronavirus still of international concern |
495 |
| Novel Coronavirus-19 (COVID-19) in the Immunocompromised Transplant Recipient |
496 |
| Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing |
497 |
| Novel Vaccine Technologies Essential Components of an Adequate Response to Emerging Viral Diseases |
498 |
| Nowcasting and forecasting the potential domestic and |
499 |
| O Anestesiologista e a COVID-19 |
500 |
| On the frontline against COVID-19 Community pharmacists’ contribution |
501 |
| On the Frontline of the COVID-19 Outbreak Keeping Patients on Long-Term Dialysis Safe |
502 |
| One in four coronavirus patients have NO symptoms |
503 |
| One size does not fit all – Patterns of vulnerability and resilience in the |
504 |
| ORIGINALStratégie pour la pratique de la chirurgiedigestive et oncologique en situationd’épidémie de COVID-19 |
505 |
| Origins of MERS-CoVand lessons for 2019-nCoV |
506 |
| Outbreak of a new coronavirus what anaesthetists should know |
507 |
| Outbreak of coronavirus disease 2019 |
508 |
| Outbreak of novel Corona virus (2019-nCoV); implications for travelers to Pakistan |
509 |
| Outcome-of-Coronavirus-spectrum-infections--SARS--M_2020_American-Journal-of |
510 |
| Overlapping and discrete aspects of the pathology and |
511 |
| Overview of guidance for endoscopy during the coronavirus disease 2019 (COVID-19) pandemic |
512 |
| Pages from [Human Respiratory Viral Infections-2014] |
513 |
| Pages from [Molecular and Cellular Biology of Viruses-2019] |
514 |
| Pages from [Polymerase Chain Reaction for Biomedical Applications-2016] |
515 |
| Pandemics and the great evolutionary mismatch |
516 |
| pannu_-_policy_brief_-_covid_series_-_turning_the_tables_on_pandemic_drugs_achieving_in-advance_therapeutics_-_v1 |
517 |
| Passengers’ destinations from China low risk of |
518 |
| Pathogenicity-and-transmissibility-of-2019-nCoV-A-quick-ove_2020_Microbes-an |
519 |
| |
520 |
| Pathological findings of COVID-19 associated with acute |
521 |
| Patient education Coronavirus disease 2019 (COVID-19) (The Basics) |
522 |
| Patient Education_Novel Coronavirus Infection |
523 |
| Patients of COVID-19 may benefit from sustained lopinavir-combined |
524 |
| Patients with advanced basal cell carcinomas in treatment with sonic hedgehog |
525 |
| Pay attention to situation of SARS-CoV-2 and TCM advantages in |
526 |
| Pediatric Middle East Respiratory Syndrome |
527 |
| Persistence of coronaviruses on inanimate surfaces and |
528 |
| Persons Evaluated for 2019 Novel Coronavirus — United States, January 2020pdf |
529 |
| Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal |
530 |
| Physiotherapy management for COVID-19 in the acute hospital setting clinical |
531 |
| Planning and provision of ECMO services for severe ARDS |
532 |
| Policies on the use of respiratory protection for hospital health |
533 |
| Positive result of Sars-Cov-2 in sputum from a cured patient with COVID-19 |
534 |
| Positive RT-PCR Test Results in Patients Recovered From COVID-19 |
535 |
| Positive-rate-of-RT-PCR-detection-of-SARS-CoV-2-infection-in-_2020_Clinica-C |
536 |
| Potential inhibitors against 2019-nCoV coronavirus M protease from |
537 |
| Potential of large ‘first generation’ human-to-human |
538 |
| Potential role of inanimate surfaces for the spread of |
539 |
| Potential Maternal and Infant Outcomes from |
540 |
| Practical recommendations for critical care and anesthesiology |
541 |
| Practical-Strategies-Against-the-Novel-Coronavirus-and_2020_Archives-of-Medi |
542 |
| Precautionary measures needed for ophthalmologists during pandemic of the coronavirus disease 2019 (COVID-19) |
543 |
| Precautions and Procedures for Coronary and Structural Cardiac Interventions during the |
544 |
| Precautions for Operating Room Team Members during the COVID-19 Pandemic |
545 |
| Predicting the angiotensin converting enzyme 2 (ACE2) utilizing |
546 |
| Predicting-commercially-available-antiviral-drugs-tha_2020_Computational-and |
547 |
| Predicting-the-impacts-of-epidemic-outbreaks-on-g_2020_Transportation-Resear |
548 |
| Preliminary-estimation-of-the-basic-reproduction-number-_2020_International- |
549 |
| |
550 |
| Preparation for Possible Sustained Transmission |
551 |
| Preparedness and vulnerability of African countries against |
552 |
| Preparing for theMost Critically Ill PatientsWith COVID-19 |
553 |
| Pressrelease_EASL-ESCMID_PositionPaper_Covidliver_2April2020 |
554 |
| Presumed Asymptomatic Carrier Transmission |
555 |
| Presymptomatic Transmission of SARS-CoV-2 — Singapore, January 23–March 16, 2020 |
556 |
| Prevalence-of-comorbidities-in-the-novel-Wuhan-coro_2020_International-Journ |
557 |
| Preventing a covid-19 pandemic |
558 |
| Preventing intra-hospital infection and transmission of COVID-19 in healthcare |
559 |
| Preventive measures against MERS-CoV for Hajj pilgrims |
560 |
| Probable-Pangolin-Origin-of-SARS-CoV-2-Associated-with-the-_2020_Current-Bio |
561 |
| Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19) A meta-analysis |
562 |
| Progress_stalled_on_coronaviru |
563 |
| Prolonged-Viral-Shedding-in-Feces-of-Pediatri_2020_Journal-of-Microbiology-- |
564 |
| Prophylactic Recommendation for Healthcare Workers during COVID-19 Pandemic |
565 |
| |
566 |
| Psychological crisis interventions in Sichuan Province during the 2019 novel coronavirus outbreak |
567 |
| Public Health Emergency Preparedness Globalizing Risk, |
568 |
| Public health management of personsPublic health management of persons Public health management of persons Public -T0Z__ZB5 |
569 |
| Public health might be endangered by possible prolonged |
570 |
| Public responses to the novel 2019 coronavirus (2019-nCoV) in Japan mental health |
571 |
| Pulmonary-Pathology-of-Early-Phase-2019-Novel-Coronaviru_2020_Journal-of-Tho |
572 |
| Purified coronavirus spike protein nanoparticles induce coronavirus |
573 |
| Radiological findings from 81 patients with COVID-19 |
574 |
| Radiotherapy Workflow and Protection Procedures During the Coronavirus |
575 |
| Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases |
576 |
| Rapid-random-access-detection-of-the-novel-SARS-coronavirus_2020_Journal-of- |
577 |
| Rational use of face masks in the COVID-19 pandemic |
578 |
| Real-time forecasts of the COVID-19 epidemic in China from |
579 |
| Recent advances and perspectives of nucleic acid detection for |
580 |
| Recent Progress in understanding 2019 Novel Coronavirus associated with |
581 |
| Receptor_for_new_coronavirus_found |
582 |
| RECOMENDACIONES DE CONSENSO SEPAR – AEER SOBRE LA |
583 |
| Recomendaciones prácticas para el manejo |
584 |
| Recomendaciones-en-el-manejo-de-la-pandemia-por-coronavirus-SARS-_2020_Nefro |
585 |
| Recomendaciones-sobre-el-manejo-cl-nico-de-la-infecci-n-por-el-_2020_Anales- |
586 |
| Recommandations pour la prise en charge chirurgicale des cancers |
587 |
| Recommendations and guidance for providing pharmaceutical care services |
588 |
| Recommendations for coronavirus infection in rheumatic diseases treated |
589 |
| Recommendations for the surgical management of gynecological cancers |
590 |
| Recommended-prophylactic-and-management-strategies-for_2020_Chronic-Diseases |
591 |
| Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease |
592 |
| Recurrence-of-positive-SARS-CoV-2-RNA-in-C_2020_International-Journal-of-Inf |
593 |
| Redefining vulnerability in the era of COVID-19 |
594 |
| Reflexiones Derivadas De La Pandemia Covid-19 |
595 |
| Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia A Multicenter Study |
596 |
| Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study |
597 |
| Remdesivir and chloroquine effectively inhibit the recently |
598 |
| Remdesivir as a possible therapeutic option for the COVID-19 |
599 |
| Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro |
600 |
| Remdesivir-for-severe-acute-respiratory-syndrome-coro_2020_Travel-Medicine-a |
601 |
| Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 |
602 |
| Respiratory rehabilitation in elderly patients with COVID-19: A randomized controlled study |
603 |
| Respiratory support for patients with COVID-19 infection |
604 |
| Advances in Experimental Medicine and Biology |
605 |
| Respiratory virus shedding in exhaled breath and efficacy of face masks |
606 |
| Respiratory viruses in mechanically ventilated patients: a pilot study |
607 |
| Responding to Covid-19 — A Once-in-a-Century Pandemic? |
608 |
| Response to the emerging novel coronavirus outbreak |
609 |
| Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study |
610 |
| Risk-adapted Treatment Strategy For COVID-19 Patients |
611 |
| Rules on isolation rooms for suspected covid-19 cases in GP surgeries to be relaxed |
612 |
| SARS Coronavirus Redux |
613 |
| SARS to novel coronavirus – old lessons and new lessons |
614 |
SARS-CoV, MERS-CoV and now the 2019-novel CoV: Have we investigated enough about coronaviruses? – A bibliometric analysis
|
615 |
| SARS-CoV-2: a time for clear and immediate action |
616 |
| SARS-CoV-2 and COVID-19 |
617 |
| SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor |
618 |
| SARS-CoV-2: fear versus data |
619 |
| SARS-CoV-2 in wastewater: potential health risk, but also data source |
620 |
| SARS-CoV-2 infection in children:Transmission dynamics and clinical characteristics |
621 |
| SARS-CoV-2 outbreak: How can pharmacists help? |
622 |
| SARS-CoV-2 RNA more readily detected in induced sputum than in throat swabs of convalescent COVID-19 patients |
623 |
| SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients |
624 |
| SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes |
625 |
| SARS-CoV-2 turned positive in a discharged patient with COVID-19 arouses concern regarding the present standard for discharge |
626 |
| Title: Serial interval of novel coronavirus (COVID-19) infections |
627 |
| Seroprevalence of MERS-CoV in healthy adults in western Saudi Arabia, 2011–2016 |
628 |
| Several potential risks of novel coronavirus (COVID-19) pneumonia outbreaks in hospitals |
629 |
| Severe acute respiratory syndrome (SARS) |
630 |
| Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists |
631 |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges |
632 |
| Severe Acute Respiratory Syndrome (SARS) and Coronavirus disease-2019 (COVID-19): From Causes to Preventions in Hong Kong |
633 |
| Shell disorder analysis predicts greater resilience of the SARS-CoV-2 (COVID-19) outside the body and in body fluids |
634 |
| Similarity in Case Fatality Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China |
635 |
| Simulating and forecasting the cumulative confirmed cases of SARS-CoV-2 in china by Boltzmann function-based regression analyses |
636 |
| Society guideline links: Coronavirus disease 2019 (COVID-19) |
637 |
| SOGC Committee Opinion– COVID-19 in Pregnancy |
638 |
| Spatial epidemic dynamics of the COVID-19 outbreak in China |
639 |
| Clinical guide for the management of people with diabetes during the coronavirus pandemic |
640 |
| Clinical guide for the management of haemoglobinopathy patients (sickle cell disease and thalassaemia) during the coronavirus pandemic |
641 |
| Clinical guide for the management of acute burns patients during the coronavirus pandemic |
642 |
| Clinical guide for anaesthesia service reorganisation during the coronavirus pandemic |
643 |
| Clinical guide for the management of emergency department patients during the coronavirus pandemic |
644 |
| Clinical guide for the management of paediatric patients during the coronavirus pandemic |
645 |
Clinical guide for the management of noncoronavirus patients requiring acute treatment: Cancer
|
646 |
| Clinical guide for the management of cardiology patients during the coronavirus pandemic |
647 |
| Clinical guide for the management of cardiothoracic surgery patients during theCoronavirus pandemic |
648 |
| Coronavirus: principles for increasing the nursing workforce in response to exceptional increased demand in adult critical care |
649 |
Clinical guide for the management of noncoronavirus patients requiring acute
treatmentgeneral and internal medicine during the coronavirus pandemic
|
650 |
Clinical guide for the management of critical care patients during the coronavirus pandemic
|
651 |
| Clinical guide for the management of patientsrequiring plastics treatment during the Coronavirus pandemic |
652 |
| Clinical guide for the management of vascular surgery patients during the Coronavirus pandemic |
653 |
| Clinical guide for the management of neurotrauma patients during the coronavirus pandemic |
654 |
| Clinical guide for management of patients requiring oral and maxillofacial surgery during the coronavirus pandemic |
655 |
| Clinical guide for the management of ophthalmology patients during the coronavirus pandemic |
656 |
Clinical guide for the management of trauma and orthopaedic patients during the coronavirus pandemic
|
657 |
| Clinical guide to managing the patient with a cough and a temperature during the coronavirus pandemic |
658 |
| Clinical guide: PPE for care of women with known or suspected coronavirus in labour |
659 |
| Clinical guide for the management of Radiology patients during the coronavirus pandemic |
660 |
| Clinical guide for the management of surgical patients during the coronavirus pandemic |
661 |
| Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection |
662 |
| Spinal anaesthesia for patients with coronavirus disease 2019 and possible transmission rates in anaesthetists: retrospective, singlecentre, observational cohort study |
663 |
| Appendix: Biphasic decay of infectious SARS-CoV-2 population |
664 |
| Stability of SARS-CoV-2 in different environmental conditions |
665 |
| Stability of SARS-CoV-2 in different environmental conditions |
666 |
| Steps Healthcare Facilities Can Take Now to Prepare for Coronavirus Disease 2019 (COVID-19) |
667 |
| Strategic plan for management of COVID-19 in paediatric haematology and oncology departments |
668 |
| Strategies to Prevent the Spread of COVID-19 in Long-Term Care Facilities (LTCF) |
669 |
| Strategies to promote better sleep in these uncertain times |
670 |
| Strategy for the practice of digestive andoncological surgery during the Covid-19epidemic |
671 |
| Structural and molecular modeling studies reveal a new mechanism |
672 |
| structural_studies_of_coronavirus_fusion_proteins |
673 |
| Structural-basis-of-SARS-CoV-2-3CLpro-and-anti-COVID_2020_Journal-of-Pharmac |
674 |
| Structure, Function, and Antigenicity of the SARSCoV- |
675 |
| Structure-analysis-of-the-receptor-bi_2020_Biochemical-and-Biophysical-Resea |
676 |
| Suggestions on the prevention of COVID-19 for health care workers in department of |
677 |
| Surveillance to improve evidence for community control decisions during the COVID-19 |
678 |
| Surviving Sepsis Campaign- guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19) |
679 |
| Taking the right measures to control COVID-19 |
680 |
| Teaser Recent advances in the research and development of small-molecule anti-human |
681 |
| Teicoplanin--an-alternative-drug-for-the-_2020_International-Journal-of-Anti |
682 |
| Temporal profiles of viral load in posterior oropharyngeal |
683 |
| Ten Weeks to Crush the Curve |
684 |
| TH17-responses-in-cytokine-storm-of-COVID-19--_2020_Journal-of-Microbiology- |
685 |
| The 2019 Coronavirus Learning Curves, Lessons, and the Weakest Link |
686 |
| The 2019-new coronavirus epidemic evidence for virus evolution |
687 |
| The Anesthesiologist and COVID-19 |
688 |
| The Battle Against Coronavirus Disease |
689 |
| The cancellation of mass gatherings (MGs) Decision making in the time of |
690 |
| The continuing 2019-nCoV epidemic threat of novel coronaviruses |
691 |
| The coronavirus 2019-nCoV epidemic Is hindsight 2020 |
692 |
| The course of clinical diagnosis and treatment of a case infected |
693 |
| The Covid-19 epidemic |
694 |
| The COVID-19 Pandemic Important Considerations for Contact Lens Practitioners |
695 |
| The COVID-19 pandemic through the lens of a gastroenterology fellow looking for the |
696 |
| The deadly coronaviruses, The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China |
697 |
| The effect of control strategies to reduce social mixing on |
698 |
| The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak |
699 |
| The effects of Nigella sativa (Ns), Anthemis hyalina (Ah) and Citrus |
700 |
| The emotional impact of Coronavirus 2019-nCoV (new Coronavirus disease) |
701 |
| The enlightenment from two cases of asymptomatic infection withSARS-CoV-2: is it safe after 14 days of isolation? |
702 |
| The GReek study in the Effects of Colchicine in COvid-19 complications prevention |
703 |
| The impact of Coronavirus (COVID-19) on head and neck cancer patients’ care |
704 |
| The impact of the COVID-19 epidemic on the utilization of emergency dental services |
705 |
| The importance of designingand implementingparticipatory surveillancesystem: An approach as earlydetection and prevention ofnovel coronavirus(2019-nCov) |
706 |
| The untold origin story of theN95 mask |
707 |
| The neuroinvasive potential of SARS-CoV2 may be at least partially responsible for the respiratory failure of COVID-19 patients |
708 |
| The next bigthreattoglobalhealth?2019novelcoronavirus(2019-nCoV):Whatadvicecanwegivetotravellers?–InterimrecommendationsJanuary2020,fromtheLatin- mericansocietyforTravelMedicine(SLAMVI) |
709 |
| The Novel Chinese Coronavirus (2019-nCoV) Infections challenges for |
710 |
| The novel Coronavirus (SARS-CoV-2) is a one health issue |
711 |
| The novel Coronavirus (SARS-CoV-2) |
712 |
| The Novel Coronavirus Originating inWuhan, China |
713 |
| The progress of 2019 Novel Coronavirus (2019-nCoV) event |
714 |
| SARS-CoV-2 infection in children Transmission dynamics and clinical |
715 |
| The psychological impact of the COVID-19 epidemic on college |
716 |
| The risk factors associated with MERS-CoV patient fatality A global survey |
717 |
| The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin |
718 |
| The versetile heparin in covid 19 |
719 |
| The-cardiovascular-burden-of-coronavirus-disease-2019_2020_International-Jou |
720 |
| The-COVID-19-pandemic--Implications-for-_2020_Journal-of-the-American-Societ |
721 |
| Seroprevalence of MERS-CoV in healthy adults in western SaudiArabia, 2011–2016 |
722 |
| The-deadly-coronaviruses--The-2003-SARS-pandemic-and-the-_2020_Journal-of-Au |
723 |
| The-epidemiology-and-pathogenesis-of-coronavirus-disea_2020_Journal-of-Autoi |
724 |
| The-epidemiology--diagnosis-and-treatm_2020_International-Journal-of-Antimic |
725 |
| The-Middle-East-Respiratory-Syndrome-C_2020_Emerging-and-Reemerg |
726 |
| The-outbreak-of-Coronavirus-Disease-2019--COVID-1_2020_Journal-of-Infection |
727 |
| The-Possible-of-Immunotherapy-for-COVID-19--a-S_2020_International-Immunopha |
728 |
| The-SARS-CoV-2-outbreak-from-a-one-health-perspective_2020_One-Health |
729 |
| The-SARS-CoV-2-outbreak--what-we_2020_International-Journal-of-Infectious-Di |
730 |
| The-spike-glycoprotein-of-the-new-coronavirus-2019-nCoV-contai_2020_Antivira |
731 |
| The-use-of-anti-inflammatory-drugs-in-the-treatment-of-people-w_2020_Clinica |
732 |
| Thoracic Imaging in COVID-19 Infection |
733 |
| Thrombocytopenia is associated with severe coronavirus disease 2019 |
734 |
| Time Course of Lung Changes On Chest CT During Recovery From 2019 Nove |
735 |
| Timely blood glucose management for the outbreak |
736 |
| Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed |
737 |
| Timely research papers about COVID-19 in China |
738 |
| Title Clinical characteristics of 50466 hospitalized patients with 2019-nCoV infection |
739 |
| Title Potential Interventions for Novel Coronavirus in |
740 |
| Towards improving clinical management of Middle East respiratory syndrome coronavirus infection |
741 |
| Tracking the transmission and evolution of MERS-CoV |
742 |
| Traditional Chinese medicine is a resource for drug discovery against |
743 |
| Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia a descriptive genomic study |
744 |
| Transmission dynamics and evolutionary history of 2019-nCoV |
745 |
| Transmission of 2019-nCoV Infection |
746 |
| Transmission potential and severity of COVID-19 in South Korea |
747 |
| Transmission potential of the novel coronavirus (COVID-19) |
748 |
| Transmission-of-COVID-19-in-the-terminal-stage-_2020_International-Journal-o |
749 |
| Treatment and vaccines for severe acute respiratory |
750 |
| Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 |
751 |
| Treatment with interferon-a2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques |
752 |
| Trust is a key factor in the willingness of health professionals to work during the |
753 |
| Turbulent Gas Clouds and Respiratory Pathogen Emissions Potential Implications for Reducing Transmission of COVID-19 |
754 |
| Understanding COVID-19 new diagnostic guidelines - a message of reassurance from an internal medicine doctor in Shanghai |
755 |
| Understanding of COVID-19 based on current |
756 |
| Understanding of guidance for acupuncture and moxibustion |
757 |
| Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate-T5875BIS |
758 |
| Unknown unknowns – COVID-19 and potential global mortality |
759 |
| Unveiling the Origin and Transmission of 2019-nCoV |
760 |
| Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in |
761 |
| Updates on Wuhan 2019 Novel Coronavirus Epidemic |
762 |
| Upper airway symptoms in coronavirus disease 2019 |
763 |
| urgent-emergency-msk-conditions-requiring-onward-referral-23-march-2020-updated (1) |
764 |
| US Emergency Legal Responses to Novel Coronavirus |
765 |
| Use of Systemic Immunomodulatory Therapies During the Coronavirus Disease 2019 |
766 |
| Using observational data to quantify bias of traveller-derived |
767 |
| Vicarious traumatization in the general public, members, and non-members |
768 |
| Viral loads of SARS-CoV, MERS-CoV and SARS-CoV-2 in respiratory specimens What have we |
769 |
| Virtual-screening-and-repurposing-of-FDA-approved-drugs-again_2020_Life-Scie |
770 |
| What are the risks of COVID-19 infection in pregnant women |
771 |
| What goes on board aircraft Passengers include Aedes, Anopheles, 2019-nCoV |
772 |
| What if the cure for the coronavirus we...mple as taking zinc – NaturalNews |
773 |
| What is the role of rheumatologists in the era of COVID-19 |
774 |
| What next for the coronavirus response |
775 |
| What Should Gastroenterologists and Patients Know About COVID-19 |
776 |
| What We Know So Far (As of March 26, 2020) About COVID-19 – An MRT Point of |
777 |
| What's new in emergency medicine |
778 |
| What's new in family medicine |
779 |
| What's new in hospital medicine |
780 |
| What's new in infectious diseases |
781 |
| What's new in primary care |
782 |
| Where did SARSCoV-2 come from |
783 |
| WHO Director-Generals opening remarks at the media briefing on COVID-19 - 1 Apr |
784 |
| Why inequality could spread COVID-19 |
785 |
| Why is it difficult to accurately predict the COVID-19 |
786 |
| Why-are-pregnant-women-susceptible-to-COVID-19--_2020_Journal-of-Reproductiv |
787 |
| Working through the COVID-19 outbreak Rapid review and |
788 |
| World-Health-Organization-declares-global-emergency--A_2020_International-Jo |
789 |
| Would everyone wearing face masks help us slow the pandemic |
790 |
| Wuhan novel coronavirus (COVID-19) why global control is |
791 |
| US Emergency Legal Responses to Novel Coronavirus Balancing Public Health and Civil Liberties |
792 |
| Design, synthesis and molecular docking of novel triazole derivatives as potential CoV helicase inhibitors |
793 |
| Pulmonary High-Resolution Computed Tomography (HRCT) Findings of Patients with Early-Stage Coronavirus Disease 2019 (COVID-19) in Hangzhou, China |
794 |
| Respiratory virus shedding in exhaled breath and efficacy of face masks |
795 |
| Economic and Monetary Union at twenty: a stocktaking of a tumultuous second decade: introduction |
796 |
| Porcine deltacoronavirus infection alters bacterial communities in the colon and feces of neonatal iglets |
797 |
| Coronaviren: von der banalen Erkältung zum schweren Lungenversagen Chronologie einer Pandemie |
798 |
| The species Severe acute respiratory syndrome- related coronavirus: classifying 2019-nCoV and namingit |
799 |
| Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B |
800 |
| Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection |
801 |
| Community pharmacist in public health emergencies: Quick to action against the coronavirus 2019-nCoV outbreak |
802 |
| Coronavirus 2019-nCoV: A brief perspective from the front line |
803 |
| Clinical characteristics and imaging manifestations of the 2019 novelcoronavirus disease (COVID-19):A multi-center study in Wenzhou city,Zhejiang, China |
804 |
| Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2 |
805 |
| Characteristics of COVID-19 infection in Beijing |
806 |
| Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts |
807 |
| Respiratory viral infection in lung transplantation induces exosomes that trigger chronic rejection |
808 |
| Corona Virus International Public Health Emergencies: Implications for Radiology Management |
809 |
| Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia |
810 |
| Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus |
811 |
| A Review of Coronavirus Disease-2019 (COVID-19) |
812 |
| CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV) |
813 |
| Emerging 2019 Novel Coronavirus (2019-nCoV) Pneumonia |
814 |
| Unveiling patterns of viral pathogen infection in free-ranging carnivores of northern Portugal using a complementary methodological approach |
815 |
| Cross‐species transmission of the newly identified coronavirus 2019‐nCoV |
816 |
| Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event |
817 |
| Novel coronavirus: From discovery to clinical diagnostics |
818 |
| Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission |
819 |
| Facing a disruptive threat: how can a nuclear medicine service be prepared for the coronavirus outbreak 2020? |
820 |
| Diagnostic performance of chest CT to differentiate COVID‑19 pneumonia in non‑high‑epidemic area in Japan |
821 |
| Use of in situ simulation to evaluate the operational readiness of a high-consequence infectious disease intensive care unit |
822 |
| The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China |
823 |
| Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion |
824 |
| A Coronavirus Disease 2019 (COVID-19) Patient with Multifocal Pneumonia Treated with Hydroxychloroquine |
825 |
| Liver injury during highly pathogenic human coronavirus infections |
826 |
| The Italian coronavirus disease 2019 outbreak: recommendations from clinical practice |
827 |
| Coronavirus: the spread of misinformation |
828 |
| „Coronavirus disease 2019“ (COVID-19): update für Anästhesisten und Intensivmediziner März 2020 |
829 |
| An Epidemiological Study on COVID-19: A Rapidly Spreading Disease |
830 |
| CT image of novel coronavirus pneumonia: a case report |
831 |
| Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia inWuhan, China |
832 |
| Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review |
833 |
| COVID‑19 pneumonia: infection control protocol inside computed tomography suites |
834 |
| SARS-CoV-2 and COVID-19: The most important research questions |
835 |
| Potential impact of seasonal forcing on a SARS-CoV-2 pandemic |
836 |
| Safety and efficacy of different anesthetic regimens for parturients with COVID-19 undergoing Cesarean delivery: a case series of 17 patients |
837 |
| Clinical features of pediatric patients with COVID‑19: a report of two family cluster cases |
838 |
| Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 |
839 |
| Can the Coronavirus Disease 2019 (COVID-19) Affect the Eyes? A Review of Coronaviruses and Ocular Implications in Humans and Animals |
840 |
| Coronavirus Disease: A Review of a New Threat to Public Health |
841 |
| Immune Predictors of Mortality After Ribonucleic Acid Virus Infection |
842 |
| Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study |
843 |
| The psychological impact of quarantine and how to reduce it: rapid review of the evidence |
844 |
| The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status |
845 |
| Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19 in Wuhan |
846 |
| Coronavirus Goes Viral: Quantifying the COVID-19 Misinformation Epidemic on Twitter |
847 |
| Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation |
848 |
| Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding |
849 |
| Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019 |
850 |
| Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein |
851 |
| Genetic characterization and phylogenetic analysis of porcine deltacoronavirus (PDCoV) in Shandong Province, China |
852 |
| Swine acute diarrhea syndrome coronavirus (SADS-CoV) antagonizes interferon-β production via blocking IPS-1 and RIG-I |
853 |
| Preparing for a COVID-19 pandemic: a review of operating room outbreak response measures in a large tertiary hospitalin Singapore |
854 |
| Chest computed tomography in children with COVID-19 respiratory infection |
855 |
| Analyzing the epidemiological outbreak of COVID‐19: A visual exploratory data analysis approach |
856 |
| Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records |
857 |
| Containing 2019-nCoV (Wuhan) coronavirus |
858 |
| The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines |
859 |
| First Case of 2019 Novel Coronavirus in the United States |
860 |
| Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) |
861 |
| Clinical characteristics of 24 asymptomatic infections with COVID- 19 screened among close contacts in Nanjing, China |
862 |
| Transmission routes of 2019-nCoV and controls in dental practice |
863 |
| Stepping up infection control measures in ophthalmology during the novel coronavirus outbreak: an experience from Hong Kong |
864 |
| Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak |
865 |
| Pathogen-specific risk factors in acute outbreaks of respiratory disease in calves |
866 |
| Complete Genome Sequence of a 2019 Novel Coronavirus (SARS-CoV-2) Strain Isolated in Nepal |
867 |
| Pathogenicity and transmissibility of 2019-nCoVdA quick overview and comparison with other emerging viruses |
868 |
| Is COVID-19 receiving ADE from other coronaviruses? |
869 |
| Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China |
870 |
| The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future |
871 |
| Lessons learned from the 2019-nCoV epidemic on prevention of future infectious diseases |
872 |
| MERS-CoV infection among healthcare workers and risk factors for death: Retrospective analysis of all laboratory-confirmed cases reported to WHO from 2012 to 2 June 2018 |
873 |
| First case of Coronavirus Disease 2019 (COVID-19) pneumonia in Taiwan |
874 |
| In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus |
875 |
| Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection |
876 |
| Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry |
877 |
| Molecular Basis of Binding between Middle East Respiratory Syndrome Coronavirus and CD26 from Seven Bat Species |
878 |
| Anewcoronavirus associatedwithhuman respiratory disease inChina |
879 |
| Apneumoniaoutbreak associatedwitha newcoronavirus ofprobablebat origin |
880 |
| Important roles of dietary taurine, creatine, carnosine, anserine and 4‑hydroxyproline in human nutrition and health |
881 |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges |
882 |
| Host AAA ATPase TER94 Plays Critical Roles in Building the Baculovirus Viral Replication Factory and Virion Morphogenesis |
883 |
| Emerging and re-emerging human infectious diseases: A systematic review of the role of wild animals with a focus on public health impact |
884 |
| Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents |
885 |
| Isolation and characterization of a variant subgroup GII-a porcine epidemic diarrhea virus strain in China |
886 |
| Camelid type I interferons: Identification and functional characterization of interferon alpha from the dromedary camel (Camelus dromedarius) |
887 |
| 2019-nCoV: The Identify-Isolate-Inform (3I) Tool Applied to a Novel Emerging Coronavirus |
888 |
| Bacterial Pneumonia in Dogs and Cats: An Update |
889 |
| Global challenges in health and health care for nurses and midwives everywhere |
890 |
| Analysis of preferred codon usage in the coronavirus N genes and their implications for genome evolution and vaccine design |
891 |
| Finding an Accurate Early Forecasting Model from Small Dataset: A Case of 2019-nCoV Novel Coronavirus Outbreak |
892 |
| A recombinant infectious bronchitis virus from a chicken with a spike gene closely related to that of a turkey coronavirus |
893 |
| Novel findings from a beta coronavirus outbreak on an American Miniature Horse breeding farm in upstate New York |
894 |
| Detection and Molecular Characterization of BCoVs Circulating in Central China Based on the Full-length Spike Gene |
895 |
| Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study |
896 |
| Q&A: The novel coronavirus outbreak causing COVID-19 |
897 |
| A mathematical model for simulating the phase-based transmissibility of a novel coronavirus |
898 |
| Management strategies of neonatal jaundice during the coronavirus disease 2019 outbreak |
899 |
| Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2 |
900 |
| Characterization of spike glycoprotein ofSARS-CoV-2 on virus entry and its immunecross-reactivity with SARS-CoV |
901 |
| Is nicotine exposure linked to cardiopulmonaryvulnerability to COVID-19 in the general population? |
902 |
| Coronavirus disease 2019: What we know? |
903 |
| Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID‑19) |
904 |
| Perspective from Ecuador, the Second Country with More Confirmed Cases of Coronavirus Disease 2019 in South America: A Review |
905 |
| Common CT Findings of Novel Coronavirus Disease 2019 (COVID-19): A Case Series |
906 |
| Application of personal-oriented digital technology in preventing transmission of COVID-19, China |
907 |
| Gastrointestinal Infection Could Be New Focus for Coronavirus Diagnosis |
908 |
| Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update |
909 |
| Development Path and Urgency of further Strengthening Construction of Public Hospitals Based on Novel Coronavirus Pneumonia Treatment |
910 |
| Experience of Clinical Management for Pregnant Women and Newborns with Novel Coronavirus Pneumonia in Tongji Hospital, China |
911 |
| Preliminary Recommendations for Surgical Practice of Neurosurgery Department in the Central Epidemic Area of 2019 Coronavirus Infection |
912 |
| Responding to COVID-19 |
913 |
| Mutterschutz – auch im Zeitalter der Coronakrise |
914 |
| Focus on Mental Health During the Coronavirus (COVID-19) Pandemic: Applying Learnings from the Past Outbreaks |
915 |
| Searching an Effective Therapy for the Coronavirus Pandemic: Do We See Light at the End of the Tunnel? |
916 |
| Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond |
917 |
| CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19) |
918 |
| COVID-19 containment: China provides important lessons for global response |
919 |
| Practical considerations for performing regional anesthesia: lessons learned from the COVID-19 pandemic Conside´rations pratiques re´gionale: les lec¸ons tire´es de la pande´mie de COVID-19 pour lare´alisation de l’anesthe´sie |
920 |
| Clinical Characteristics of Children with Coronavirus Disease 2019 in Hubei, China |
921 |
| Epidemiological data from the COVID-19 outbreak, real-time case information |
922 |
| Brief Review on COVID-19: The 2020 Pandemic Caused by SARS-CoV-2 |
923 |
| Factors Associated With Mental Health Outcomes Among Health CareWorkers Exposed to Coronavirus Disease 2019 |
924 |
| Coronavirus disease 2019 (COVID-19): update for anesthesiologists and intensivists |
925 |
| Coronavirus disease 2019: initial chest CT findings |
926 |
| Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Coronavirus Disease 2019 (COVID-19)Treatment of |
927 |
| Coronavirus (COVID-19): A Review of Clinical Features, Diagnosis, and Treatment |
928 |
| The effect of timing on community acquired respiratory virusinfection mortality epidemiological surveyhematopoietic stem cell transplantation: a prospectiveduring the first year after allogeneic |
929 |
| Neurological Complications of Coronavirus Disease(COVID-19): Encephalopathy |
930 |
| A Bibliometric Analysis of COVID-19 Research Activity: A Call for Increased Output |
931 |
| Understanding the Mosaic of COVID-19: A Review of the Ongoing Crisis |
932 |
| Insights from nanomedicine into chloroquine efficacy against COVID-19 |
933 |
| Protecting healthcare personnel from 2019-nCoV infection risks: lessons and suggestions |
934 |
| COVID-19 epidemic in Switzerland: on the importance of testing, contact tracing and isolation |
935 |
| Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review |
936 |
| Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center’s observational study |
937 |
| Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBDprotein as a viral attachment inhibitor and vaccine |
938 |
| AI-Driven Tools for Coronavirus Outbreak: Need of Active Learning and Cross-Population Train/Test Models on DataMultitudinal/Multimodal |
939 |
| Coronavirus disinfection in histopathology |
940 |
| Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools |
941 |
| Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than coronavirus‐associated illnessesneutralizing antibodies in identifying |
942 |
| Potential interventions for novel coronavirus in China: A systematic review |
943 |
| Immunoinformatics‐aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019‐nCoV |
944 |
| Immune responses in COVID-19 and potential vaccines:Lessons learned from SARS and MERS epidemic |
945 |
| Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19) |
946 |
| COVID-19: The outbreak caused by a new coronavirus |
947 |
| Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19) |
948 |
| Middle East Respiratory Syndrome-Coronavirus Infection into Established hDPP4-Transgenic Mice Accelerates Lung Damage Via Activation of the Pro-Inflammatory Response and Pulmonary Fibrosis |
949 |
| Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic |
950 |
| Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19) |
951 |
| Comparison of relative expressions of genes involved in iron acquisition and regulation in fluoroquinolone-resistant and wild-type Campylobacter jejuni |
952 |
| Coinfection with porcine circovirus type 2 and Streptococcus suis serotype 2 enhances pathogenicity by dysregulation of the immune responses in piglets |
953 |
| Pathogenicity of a variant duck orthoreovirus strain in Cherry Valley Ducklings |
954 |
| A quickly, effectively screening process of novel corona virus disease 2019 (COVID-19) in children in Shanghai, China |
955 |
| COVID-19: The outbreak caused by a new coronavirus |
956 |
| Severe underlying liver diseases and high mortality associated with Laribacter hongkongensis bacteremia |
957 |
| Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection |
958 |
| Aureimonas altamirensis masquerading as Brucella spp. in a blood culture from a 68-year-old male with cancer |
959 |
| Fosfomycin resistance mediated by fos genes remains rare among extended-spectrum beta-lactamase-producing Escherichia coli hospitals (CANWARD, 2007–2017)clinical |
960 |
| Matrix-assisted laser desorption ionization-time of flight mass spectrometry can be used to identify Helicobacter cinaedi |
961 |
| Clinical impact of molecular identification of rare yeasts and nonsporulating molds recovered in culture from clinical specimens |
962 |
| Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development |
963 |
| Influence of interferon-based drugs on immunological indices in specific prevention |
964 |
| Estimation of the Transmission Risk of the 2019-nCoV and Its Implication for Public Health Interventions |
965 |
| Real-Time Estimation of the Risk of Death from Novel Coronavirus (COVID-19) Infection: Inference Using Exported Cases |
966 |
| Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A StatisticalPublicly Available Case Data Analysis of |
967 |
| Risk Assessment of Novel Coronavirus COVID-19 Outbreaks Outside China |
968 |
| Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China |
969 |
| Short-term Forecasts of the COVID-19 Epidemic in Guangdong and Zhejiang, China: February 13–23, 2020 |
970 |
| Assessing the Impact of Reduced Travel on Exportation Dynamics of Novel Coronavirus Infection (COVID-19) |
971 |
| Novel Coronavirus Outbreak in Wuhan, China, 2020:Intense Surveillance Is Vital for Preventing Sustained Transmission in New Locations |
972 |
| Estimating the Unreported Number of Novel Coronavirus (2019-nCoV) Cases in China in the First Half of January 2020: A Data-Driven Analysis of the Early OutbreakModelling |
973 |
| Discovering drugs to treat coronavirus disease 2019 (COVID-19) |
974 |
| Early estimation of the case fatality rate of COVID-19 in mainland China: a data-driven analysis |
975 |
| A 25-Year-Old Sample Contributes the Complete GenomeSequence of Avian Coronavirus Vaccine Strain ArkDPI,Reisolated from Commercial Broilers in the United States |
976 |
| Complete Genome Sequence of Avian Coronavirus Strain GA08 |
977 |
| Disrupting the association of Autographa californica multiple egress of nucleocapsids and intranuclear microvesicles formationnucleopolyhedrovirus Ac93 with cellular ESCRT-III/Vps4 hinders nuclear |
978 |
| Hepatitis E viral infection causes testicular damage in mice |
979 |
| Comparative analysis of the viral interferon regulatory factors of KSHV for their requisite for virus production and inhibition of the type I interferon pathway |
980 |
| CSFV protein NS5A activates the unfolded protein response to promote viral replication |
981 |
| Inhibitors of the interferon response increase the replication of gorilla simian foamy viruses |
982 |
| Middle East Respiratory Syndrome Coronavirus Transmission |
983 |
| Porcine Deltacoronavirus Infection and Transmission in Poultry, United States1 |
984 |
| Interferon-stimulated genes inhibit caprine parainfluenza virus type 3 replication in Madin-Darby bovine kidney cells |
985 |
| Experimental listeriosis: A study of purinergic and cholinergic inflammatory pathway |
986 |
| Evaluation of a novel inactivated vaccine against duck circovirus in muscovy ducks |
987 |
| Gastrointestinal Symptoms & stool viral RNA positivity rate in COVID-19 |
988 |
| Poxvirus encoded eIF2α homolog, K3 family proteins, is a key determinant of poxvirus host species specificity |
989 |
| Chinese expert consensus on the perinatal and neonatal management for the prevention and control of the 2019 novel coronavirus infection (First edition) |
990 |
| Which lessons shall we learn from the 2019 novel coronavirus outbreak? |
991 |
| Synthesis and structure-activity relationship studies ofa-naphthoflavone derivatives as CYP1B1 inhibitors |
992 |
| Fluorine-substituted tetracationic ABAB-phthalocyanines for efficient bacteria photodynamic inactivation of Gram-positive and Gram-negative |
993 |
| The discovery of novel indazole derivatives as tubulin colchicine sitebindingand in vivo agents that displayed potent antitumor activity both in vitro |
994 |
| through peroxisome proliferator-activated receptor g modulation |
995 |
| Depletion of miR-380 mitigates human bronchial epithelial cells injury toimprove chronic obstructive pulmonary disease through targeting CHRNA4 |
996 |
| LGI3 is secreted and binds to ADAM22 via TRIF-dependent NF-κB pathwayin response to LPS in human keratinocytes |
997 |
| Increased levels of inflammatory biomarker CX3CL1 in patients with chronicobstructive pulmonary disease |
998 |
| Physical training prior to myocardial infarction potentializes stem celltherapy, response in hypertensive ratsSDF-1/CXCR4 axis activation and inhibits the vasoconstrictor |
999 |
| A time delay dynamic system with external source for the local outbreak of 2019-nCoV |
1000 |
| Visualising the expansion and spread of coronavirus disease 2019 by cartograms |
1001 |
| Phase-adjusted estimation of the number of Coronavirus Disease 2019 cases in Wuhan, China |
1002 |
| Finding equipoise: CEPI revises its equitable access policy |
1003 |
| High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa |
1004 |
| Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses |
1005 |
| Does SARS‐CoV‐2 has a longer incubation period than SARS and MERS? |
1006 |
| A numerical study of ventilation strategies for infection risk mitigation in general inpatient wards |
1007 |
| Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding |
1008 |
| Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS‐CoV, MERS‐CoV, and 2019‐nCoV |
1009 |
| MiR-10a-5p-Mediated Syndecan 1 Suppression Restricts Porcine Hemagglutinating Encephalomyelitis Virus Replication |
1010 |
| A Novel Coronavirus from Patients with Pneumonia in China, 2019 |
1011 |
| 2019 novel coronavirus of pneumonia inWuhan, China: emerging attack and management strategies |
1012 |
| Demographic Variations of MERS-CoV Infection among Suspected and Confirmed Cases: An Epidemiological Analysis of Laboratory-Based Data from Riyadh Regional Laboratory |
1013 |
| Does SARS‐CoV‐2 has a longer incubation period than SARS and MERS? |
1014 |
| A numerical study of ventilation strategies for infection risk mitigation in general inpatient wards |
1015 |
| Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding |
1016 |
| Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS‐CoV, MERS‐CoV, and 2019‐nCoV |
1017 |
| MiR-10a-5p-Mediated Syndecan 1 Suppression Restricts Porcine Hemagglutinating Encephalomyelitis Virus Replication |
1018 |
| A Novel Coronavirus from Patients with Pneumonia in China, 2019 |
1019 |
| 2019 novel coronavirus of pneumonia inWuhan, China: emerging attack and management strategies |
1020 |
| Demographic Variations of MERS-CoV Infection among Suspected and Confirmed Cases: An Epidemiological Analysis of Laboratory-Based Data from Riyadh Regional Laboratory |
1021 |
| Genomic variance of the 2019‐nCoV coronavirus |
1022 |
| Expression Pattern Analysis of Antiviral Genes and Inflammatory Cytokines in PEDV-Infected Porcine Intestinal Epithelial Cells |
1023 |
| 2019 Novel coronavirus: where we are and what we know |
1024 |
| Effects of misleading media coverage on public health crisis: a case of the 2019 novel coronavirus outbreak in China |
1025 |
| Fatal encephalitis associated with coronavirus OC43 in an immunocompromised child |
1026 |
| Bat-borne viruses in Africa: a critical review |
1027 |
| The Effects of Social Media Use on Preventive Behaviors during Infectious Disease Outbreaks: The Mediating Role of Self-relevant Emotions and Public Risk Perception |
1028 |
| Activation of C-Type Lectin Receptor and (RIG)-I-Like Receptors Contributes to Proinflammatory Response in Middle East Respiratory Syndrome Coronavirus-Infected Macrophages |
1029 |
| Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China |
1030 |
| Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study |
1031 |
| A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster |
1032 |
| Evaluation of an octahydroisochromene scaffold used as a novel SARS 3CL protease inhibitor |
1033 |
| The First Disease X is Caused by a Highly Transmissible Acute Respiratory Syndrome Coronavirus |
1034 |
| Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study |
1035 |
| Potential of large “first generation” human‐to‐human transmission of 2019‐nCoV |
1036 |
| Transmission dynamics and evolutionary history of 2019‐nCoV |
1037 |
| Public awareness of coronavirus in Al-Jouf region, Saudi Arabia |
1038 |
| Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China |
1039 |
| Non‑influenza respiratory viruses in adult patients admitted with influenza‑like illness: a 3‑year prospective multicenter study |
1040 |
| Respiratory viruses in mechanically ventilated patients: a pilot study |
1041 |
| The global spread of 2019-nCoV: a molecular evolutionary analysis |
1042 |
| Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients Directives concre`tes `a l’intention des e´quipes de soins intensifs et d’anesthe´siologie prenant soin de patients atteints du coronavi |
1043 |
| The first two cases of 2019‐nCoV in Italy: Where they come from? |
1044 |
| Development of an indirect ELISA for detecting porcine deltacoronavirus IgA antibodies |
1045 |
| Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, China |
1046 |
| PEDV enters cells through clathrin-, caveolae-, and lipid raft-mediated endocytosis and traffics via the endo-/lysosome pathway |
1047 |
| Epidemiologic characteristics of early cases with 2019 novel coronavirus (2019-nCoV) disease in Korea |
1048 |
| Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts’ consensus statement |
1049 |
| Emerging coronaviruses: Genome structure, replication, and pathogenesis |
1050 |
| Associations of the IL-1B level, IL-1A and IL-1B gene polymorphisms andankylosing spondylitis risk in a Chinese Han population |
1051 |
| Chemokine (C-C motif) ligand 2 and coronary artery disease: Tissueexpression of functional and atypical receptors |
1052 |
| Cell proliferation activity delineated by molecular docking of four F. Gmelnewcompounds isolated from the aerial parts of Suaeda monoica Forssk. ex. J. |
1053 |
| Dispensing errors and self-medication practice observed by communitypharmacists in Jordan |
1054 |
| Time and sex dependency of hemodynamic, renal, and survivabilityeffects of endotoxemia in rats |
1055 |
| Optimization and evaluation of novel tetrahydropyrido[4,3-d]pyrimidine fibrosisderivatives as ATX inhibitors for cardiac and hepatic |
1056 |
| A second-generation micro/nano capsules of an endogenous primaryun-antioxidant compoundsmetabolised bile acid, stabilized by Eudragit-alginate complex with |
1057 |
| Association of OprF mutant and disturbance of biofilm and pyocyaninvirulence in pseudomonas aeruginosa |
1058 |
| Evidence that changes in antimicrobial peptides during tuberculosis arerelated to of immune-endocrine mediatorsdisease severity, clinical presentation, specific therapy and levels |
1059 |
| Pathogen-specific risk factors in acute outbreaksof respiratory disease in calves |
1060 |
| Association between ABCB1, ABCG2 carrier protein and COX-2 enzymegene polymorphisms and breast cancer risk in a Turkish population |
1061 |
| Semisynthesis and biological evaluation of some novel Mannich basederivatives agentsagentsderived from a natural lignan obovatol as potential antifungal |
1062 |
| Gga-miR-30d regulates infectious bronchitis virus infection by targetingUSP47 in HD11 cells |
1063 |
| Attenuation and characterization of porcine enteric alphacoronavirus strainGDS04 via serial cell passage |
1064 |
| Origin recognition complex subunit 1 regulates cell growth and metastasis inglioma by altering activation of ERK and JNK signaling pathway |
1065 |
| Combining Procalcitonin and Rapid Multiplex Respiratory VirusTesting for Severe Acute Respiratory InfectionAntibiotic Stewardship in Older Adult Patients With |
1066 |
| Nucleocapsid Protein Recruitment to Replication-TranscriptionComplexes Plays a Crucial Role in Coronaviral Life Cycle |
1067 |
| Coronavirus disease 2019 Mehr Sicherheit durch kompakte Fakten und Handlungsempfehlungen |
1068 |
| Lidocaine during intubation and extubation in patients with coronavirus disease (COVID-19) |
1069 |
| Uncertainty in using chest computed tomography in early coronavirus disease (COVID-19) |
1070 |
| Chest computed tomography images of early coronavirus disease (COVID-19) |
1071 |
| New coronavirus: new challenges for pediatricians |
1072 |
| Correction to: COVID-19: a novel coronavirus and a novel challenge for critical care |
1073 |
| Using echocardiography to guide the treatment of novel coronavirus pneumonia |
1074 |
| How to face the novel coronavirus infection during the 2019–2020 epidemic: the experience of Sichuan Provincial People’s Hospital |
1075 |
| The impact of high-flow nasal cannula (HFNC) on coughing distance: implications on its use during the novel coronavirus disease outbreak |
1076 |
| Take precautions beforehand: calling for clinical trials of pediatric drugs for treating coronavirus disease 2019 |
1077 |
| A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19 |
1078 |
| Coronavirus: just imagine… |
1079 |
| The novel coronavirus (SARS-CoV-2) infections in China: prevention, control and challenges |
1080 |
| Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue |
1081 |
| Novel coronavirus infection during the 2019–2020 epidemic: preparing intensive care units—the experience in Sichuan Province, China |
1082 |
| Practice of novel method of bedside postpyloric tube placement in patients with coronavirus disease 2019 |
1083 |
| Simulation as a tool for assessing and evolving your current personal protective equipment: lessons learned during the coronavirus disease (COVID-19) pandemic |
1084 |
| In reply: Uncertainty in using chest computed tomography in early coronavirus disease (COVID-19) |
1085 |
Intensive care during the coronavirus
epidemic |
1086 |
| Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus |
1087 |
| Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients Directives concre`tes `a l’intention des e´quipes de soins intensifs et d’anesthe´siologie prenant soin de patients atteints du coronavi |
1088 |
| COVID-19: a novel coronavirus and a novel challenge for critical care |
1089 |
| Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts’ consensus statement |
1090 |
| Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019 |
1091 |
| Coronavirus disease 2019“ (COVID-19): update für Anästhesisten und Intensivmediziner März 2020 |
1092 |
| Coronavirus disease 2019 (COVID-19): update for anesthesiologists and intensivists March 2020 |
1093 |
| Management strategies of neonatal jaundice during the coronavirus disease 2019 outbreak |
1094 |
| The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China |
1095 |
| Clinical features of severe pediatric patients with coronavirus disease 2019 inWuhan: a single center’s observational study |
1096 |
| Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19) |
1097 |
| Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists |
1098 |
| Practical considerations for performing regional anesthesia: lessons learned from the COVID-19 pandemic Conside´rations pratiques pour lare´alisation de l’anesthe´sie re´gionale: les lec¸ons tire´es de la pande´mie de COVID-19 |
1099 |
| German recommendations for critically ill patients with COVID-19 |
1100 |
| Safety and efficacy of different anesthetic regimens for parturients with COVID-19 undergoing Cesarean delivery: a case series of 17 patients Se´curite´ et efficacite´ de diffe´rents modes d’anesthe´sie pour des parturientes infecte´es par la COVID-19 accou |
1101 |
| Personal Protection Prior to Preoperative Assessment—Little more an anaesthesiologist can do to prevent SARS- CoV-2 transmission and COVID-19 infection |
1102 |
| COVID-19 and the RAAS—a potential role for angiotensin II? |
1103 |
| Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis |
1104 |
| VID-19 pandemic: the 3R’s (reduce, refine, and replace) of personal protective equipment (PPE) sustainability |
1105 |
| Critical care management of adults with community-acquired severe respiratory viral infection |
1106 |
How to transform a general hospital into
an “infectious disease hospital” during the
epidemic of COVID-19 |
1107 |
| Mutterschutz – auch im Zeitalter der Coronakrise |
1108 |
| Diagnosis of severe respiratory infections in immunocompromised patients |
1109 |
| Preparing for a COVID -19 pandemic: a review of operating room outbreak response measures in a large tertiary hospital in Singapore Se pre´parer pour la pande´mie de COVID -19: revue des moyens de´ploye´s dans un bloc ope´ratoire d’un grand hopital tertiai |
1110 |
| Social distancing: implications for the operating room in the face of COVID-19 |
1111 |
| Clinical features and short-term outcomes of 18 patients with corona virus disease 2019 in intensive care unit |
1112 |
| COVID-19 infection epidemic: the medical management strategies in Heilongjiang Province, China |
1113 |
| What we do when a COVID-19 patient needs an operation: operating room preparation and guidance |
1114 |
| Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target |
1115 |
| Clinical features of pediatric patients with COVID‑19: a report of two family cluster cases |
1116 |
| Japan ECMOnet for COVID-19: telephone consultations for cases with severe respiratory failure caused by COVID-19 |
1117 |
| Acute kidney injury in SARS-CoV-2 infected patients |
1118 |
| A case of a readmitted patient who recovered from COVID-19 in Chengdu, China |
1119 |
| Empfehlungen zur intensivmedizinischen Therapie von Patienten mit COVID-19 |
1120 |
| Respiratory viruses in mechanically ventilated patients: a pilot study |
1121 |
| The application of strong matrix management and PDCA cycle in the management of severe COVID-19 patients |
1122 |
| Critical care crisis and some recommendations during the COVID-19 epidemic in China |
1123 |
| Clear plastic drapes may be effective at limiting aerosolization and droplet spray during extubation: implications for COVID-19 |
1124 |
| Preparing for COVID-19: early experience from an intensive care unit in Singapore |
1125 |
| European Society of Trauma and Emergency Surgery (ESTES) recommendations for trauma and emergency surgery preparation during times of COVID‑19 infection |
1126 |
| Challenges and countermeasures for organ donation during the SARS-CoV-2 epidemic: the experience of Sichuan Provincial People’s Hospita |
1127 |
| Imaging changes of severe COVID-19 pneumonia in advanced stage |
1128 |
| Prognosis when using extracorporeal membrane oxygenation (ECMO) for critically ill COVID-19 patients in China: a retrospective case series |
1129 |
| Summary of 20 tracheal intubation by anesthesiologists for patients with severe COVID‑19 pneumonia: retrospective case series |
1130 |
| How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People’s Hospital |
1131 |
| Common breaches in biosafety during donning and doffing of protective personal equipment used in the care of COVID-19 patients |
1132 |
| Critical care response to a hospital outbreak of the 2019-nCoV infection in Shenzhen, China |
1133 |
| Mental health advice for frontline healthcare providers caring for patients with COVID-19 |
1134 |
| Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan |
1135 |
| Familial cluster of COVID-19 infection from an asymptomatic |
1136 |
| Covid-19 in China: ten critical issues for intensive care medicine |
1137 |
| Lower mortality of COVID-19 by early recognition and intervention: experience from Jiangsu Province |
1138 |
| The model of epidemic (COVID-19) prevention and control in rural of China |
1139 |
| Special attention to nurses’ protection during the COVID-19 epidemic |
1140 |
| Treatment of COVID-19: old tricks for new challenges |
1141 |
| Locating and repurposing anesthetic machines as intensive care unit ventilators during the COVID-19 pandemic |
1142 |
| Clinicolaboratory study of 25 fatal cases of COVID-19 inWuhan |
1143 |
| A new clinical trial to test high-dose vitamin C in patients with COVID-19 |
1144 |
| Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients fromWuhan, China |
1145 |
| COVID-19 pneumonia: different respiratory treatments for different phenotypes? |
1146 |
| Imaging changes in severe COVID-19 pneumonia |
1147 |
| Findings of lung ultrasonography of novel corona virus pneumonia during the 2019–2020 epidemic |
1148 |
| Project IDentif.AI: Harnessing Artificial Intelligence toRapidly Optimize Combination Therapy Development forInfectious Disease Intervention |
1149 |
| SmellDysfunction:ABiomarkerforCOVID-19 |
1150 |
| SARS-CoV-2 Seroconversion in Humans:A Detailed Protocol for a SerologicalAssay, Antigen Production, and TestSetup |
1151 |
| Research and Funding in the Time of COVID-19 |
1152 |
| Turning sandstorms into pearls |
1153 |
| Drug repositioning: a brief overview |
1154 |
| The Utah Model: mental bandwidth and strategic risk generation in COVID-19 airway management |
1155 |
| How we deal with the COVID-19 epidemic in an Italian pediatric onco-hematology clinic located in a region at high density of cases |
1156 |
| Estimation of basic reproduction number for COVID-19 and the reasons for its differences Hadis Najafimehr1, Kosar Mohamed Ali2, Saeed Safari3, Mahmoud Yousefifard4*, ostafa Hosseini |
1157 |
| COVID-19: 2020 a year in turmoil |
1158 |
| The prospects fortheSARS-CoV-2 pandemic in Africa |
1159 |
| A Policy to Do Better Next Time: Lessons Learned from the Covid-19 Pandemic |
1160 |
| Built-in RNA-mediated Chaperone (Chaperna) for Antigen Folding Tailored to Immunized Hosts |
1161 |
| Care of Immunocompromised Patients with Head and Neck Cancer During the COVID-19 Pandemic: Two Challenging and Informative Clinical Cases |
1162 |
| How to avoid nosocomial spread during Tracheostomy for Covid-19 patients |
1163 |
| Endocrine Surgery in the Coronavirus Disease 2019 Pandemic |
1164 |
| Disproportionate impact of COVID-19 Pandemic on Head and Neck Cancer Survivors |
1165 |
| Head and neck virtual medicine in a pandemic era: lessons from COVID-19 |
1166 |
| Management of the Difficult Airway in the COVID-19 Pandemic: An Illustrative Complex Head and Neck Case Scenario |
1167 |
| A Commentary on the Management of Total Laryngectomy PatientsDuring the COVID-19 Pandemic |
1168 |
| A Framework for Prioritizing Head and Neck Surgery during the COVID-19 Pandemic |
1169 |
| Failure in initial stage containment of global COVID-19 epicenters |
1170 |
| COVID-19: Recommended sampling sites at different stage of the disease |
1171 |
| Case fatality rate analysis of Italian COVID-19 outbreak |
1172 |
| Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement |
1173 |
| Off-label UseofTocilizumab in Patients with SARS-CoV-2 Infection |
1174 |
| VIROLOGICAL AND CLINICAL CURE IN COVID-19 PATIENTS TREATED WITH HYDROXYCHLOROQUINE: A SYSTEMATIC REVIEW AND META-ANALYSIS |
1175 |
| High IL-6/IFN-γ ratio could be associated withsevere disease in COVID-19 patients |
1176 |
| The use of UV fluorescent powder for COVID-19 airway management simulationtraining |
1177 |
| The role of childrenin the transmission of mildSARS-CoV-2 infection |
1178 |
| Relationships among Lymphocyte Subsets, Cytokines, and the Pulmonary Inflammation Index in 10Coronavirus (COVID-19) Infected Patients |
1179 |
| Reactive lymphocytes in patients with Covid‐19 |
1180 |
| Management of COVID-19 Related Paediatric Blood Samples in a Clinical Haematology Laboratory |
1181 |
| Guide to Immunopharmacology: a database to boost immunologyeducation, research and therapy |
1182 |
| Non-cutaneous considerations of COVID19 for dermatology practices |
1183 |
| COVID-19and student nurses: a view from England |
1184 |
| Management of Infantile Hemangiomas during the COVID Pandemic |
1185 |
| How to Guarantee the Best of Care to Patients with CancerDuring the COVID-19 Epidemic: The Italian Experience |
1186 |
| CORRESPONDANCE Reflections and New Developments within the COVID-19 Pandemic |
1187 |
| REPLY(by Kevin Welch)to Zara Patel CORRESPONDENCE |
1188 |
| Telesupported procedures:when and how |
1189 |
| EMPLOYING DERMATOLOGISTS ON THE FRONTLINE AGAINST COVID-19: ALL HANDS ON DECK |
1190 |
| CORONAVIRUS-DAYS IN DERMATOLOGY |
1191 |
| Improving Communication About COVID-19 and Other Emerging Infectious Diseases |
1192 |
| Exaggerated information and COVID-19 outbreak |
1193 |
| Concerns related to COVID-19 pandemic among patients with Inflammatory Bowel Disease, and its influence on patients management. |
1194 |
| On the alert for cytokine storm: Immunopathology in COVID-19 |
1195 |
| Global guidance for surgical care during theCOVID-19 pandemic |
1196 |
| Moving biochemistry and molecular biology coursesonline in times of disruption: Recommended practicesand resources - a collaboration with the faculty communityand ASBMB |
1197 |
| Coronavirus and the hearts of doctors |
1198 |
| Coronavirus, Climate Change, and a Bit of Hope |
1199 |
| Could HIV infection alter the clinical course of SARS-CoV-2 infection? When less is better |
1200 |
| Treatment with convalescent plasma for COVID-19 patientsin Wuhan, China |
1201 |
| Clinical characteristics of COVID-19: a meta-analysis |
1202 |
| Possibly critical role of wearing masks in general population in controllingCOVID-19 |
1203 |
| Hyperglycemia, Hydroxychloroquine, and the COVID-19 Epidemic |
1204 |
| Concomitant neurological symptomsobserved in a patient diagnosed with coronavirus disease 2019 |
1205 |
Does COVID-19 Disprove the Obesity Paradox in ARDS
|
1206 |
| The Impact of COVID-19 on Bariatric Surgery: Re-Defining Psychosocial Care |
1207 |
| The impact of COPD and smoking history onthe severity of Covid-19:A systemic review and meta-analysis |
1208 |
| Coinfection with COVID-19 and Coronavirus HKU1 –the critical need for repeat testing if clinically indicated |
1209 |
| Analysis of 92 deceased patients with COVID-19 |
1210 |
| SARS-CoV-2: at the crossroad between aging and neurodegeneration |
1211 |
| COVID-19 VAGINAL DELIVERY – A CASE REPORT |
1212 |
| Letter to the Editor Re: Coronavirus disease 2019: The harms of exaggerated information and non-evidence-based measures |
1213 |
| SARS-CoV-2, an evolutionary perspective of interaction with human ACE2 reveals undiscovered amino acids necessary for complex stability |
1214 |
| The Neverending Shift: A feminist reflectiononliving and organisingacademic livesduring the Coronavirus pandemic |
1215 |
| Norming COVID-19: The Urgency of a Non-Humanist Holism |
1216 |
| SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor |
1217 |
| Viral exanthem in COVID-19, a clinical enigma with biological significance |
1218 |
| Comment on: Cutaneous manifestations in COVID-19: a first perspective. Safety concerns of clinical images and skin biopsies |
1219 |
A distinctive skin rash associated with Coronavirus Disease 2019
|
1220 |
| All roads lead to coronavirus |
1221 |
| Amiodarone as a possible therapy for coronavirus infection |
1222 |
| The pandemic of coronavirus: tackling the latest plague |
1223 |
| 2019 CORONAVIRUS: What are the implications for cardiology? |
1224 |
| Feline coronavirus-associated myocarditis in a domestic longhair cat |
1225 |
| Psychological assistance during the coronavirus disease 2019 outbreak in China |
1226 |
| Coronavirus Disease 2019 (COVID-19): Considerations for the Competitive Athlete |
1227 |
| Pediatric Characteristics of 2019 Novel Coronavirus: Review of Available Published Literature |
1228 |
| Visualising the expansion and spread of coronavirus disease 2019 by cartograms |
1229 |
| Telehealth for global emergencies: Implications for coronavirus disease 2019 (COVID-19) |
1230 |
| The outbreak of COVID-19 coronavirus and its impact on global mental health |
1231 |
| Structure of the SARS-Unique Domain C From the Bat Coronavirus HKU4 |
1232 |
| Electrolyte Imbalances in Patients with Severe Coronavirus Disease 2019 (COVID-19) |
1233 |
| Effect of cat litters on feline coronavirus infection of cell culture and cats |
1234 |
| Coronavirus Disease 2019 (COVID-19): Emerging and Future Challenges for Dental and Oral Medicine |
1235 |
| Care of patients with Pulmonary Arterial Hypertension during the Coronavirus (COVID-19) Pandemic |
1236 |
| Physical inactivity and cardiovascular disease at the time of coronavirus disease 2019 (COVID-19) |
1237 |
| Narrative review of Middle East respiratory syndrome coronavirus (MERS-CoV) infection: updates and implications for practice |
1238 |
| COVID-19 infodemic: More retweets for science-basedinformation on coronavirus than for false information |
1239 |
| Detection of feline coronavirus mutations in paraffin-embedded tissues in cats with feline infectious peritonitis and controls |
1240 |
| Distinct mutation in the feline coronavirus spike protein cleavage activation site in a cat with feline infectious peritonitis-associated meningoencephalomyelitis |
1241 |
| Feline coronavirus with and without spike gene mutations detected by real-time RT-PCRs in cats with feline infectious peritonitis |
1242 |
| Preliminary investigation on feline coronavirus presence in the reproductive tract of the tom cat as a potential route of viral transmission |
1243 |
| Does the direct renin inhibitor have a role to play in attenuating severity of the outbreak coronavirus disease 2019 (COVID-19)? |
1244 |
| Severe acute respiratory syndrome coronavirus 2 infection, angiotensin- converting enzyme 2 and treatment with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers |
1245 |
| A dialogue between the editor-in-chief and a deputy editor of a cardiology journal during the coronavirus outbreak: Take-home messages from the Italian experience |
1246 |
| Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study |
1247 |
| Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease |
1248 |
| Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province |
1249 |
| Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model |
1250 |
| Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study |
1251 |
| Pediatric Endoscopy in the Era of COVID-19: A NASPGHAN Position Paper |
1252 |
| Cardiovascular Considerations in Treating Patients with Coronavirus (COVID-19) |
1253 |
| Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study |
1254 |
| Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease |
1255 |
| Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province |
1256 |
| Computed Tomography Manifestations of 5 Cases of the Novel Coronavirus Disease 2019 (COVID-19) Pneumonia From Patients Outside Wuhan |
1257 |
| High-Resolution Computed Tomography Manifestations of 5 Pediatric Patients With 2019 Novel Coronavirus |
1258 |
| Mental Health Care Providers Dealing With Coronavirus Disease 2019 (COVID-19): What Is the Definition of a Case, How Is That Changing, and What Kinds of Tests Are Available? |
1259 |
| Clinical Pathway for Management of Suspected or Positive Novel Coronavirus-19 Patients with ST Segment Elevation Myocardial Infarction |
1260 |
| Rehospitalization of a Recovered Coronavirus Disease 19 (COVID-19) Child With Positive Nucleic Acid Detection |
1261 |
| Coronavirus Infections in Children Including COVID-19 An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children |
1262 |
| Imaging features and mechanisms of novel coronavirus pneumonia (COVID-19) Study Protocol Clinical Trial (SPIRIT Compliant) |
1263 |
| First Case of 2019 Novel Coronavirus in the United States |
1264 |
| A Novel Coronavirus from Patients with Pneumonia in China, 2019 |
1265 |
| Effect of isolation practice on the transmission of middle east respiratory syndrome coronavirus among hemodialysis patients A 2-year prospective cohort study |
1266 |
| Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19) |
1267 |
| The persistence and clearance of viral RNA in 2019 novel coronavirus disease survivors |
1268 |
| Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a randomized controlled trial |
1269 |
| Perioperative Management of Patients Infected with the Novel Coronavirus |
1270 |
| The Surgeon’s Role During the Coronavirus Pandemic |
1271 |
| Coronaviruses and SARS-CoV-2: A Brief Overview |
1272 |
| Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019 in Shanghai, China |
1273 |
| Orthopaedic Surgical Selection and Inpatient Paradigms During the COVID-19 Pandemic |
1274 |
| Coronavirus Disease 2019 (COVID-19) and Pregnancy Responding to a Rapidly Evolving Situation |
1275 |
| Obstetricians on the Coronavirus Disease 2019 (COVID-19) Front Lines and the Confusing World of Personal Protective Equipment |
1276 |
| Clinical Characteristics of Coronavirus Disease 2019 in China |
1277 |
| Coronavirus Disease 2019 in Critically Ill Children: A Narrative Review of the Literature |
1278 |
| Protected Code Stroke Hyperacute Stroke Management During the Coronavirus Disease 2019 (COVID-19) Pandemic |
1279 |
| Chest CT Findings in Patients With Coronavirus Disease 2019 and Its Relationship With Clinical Features |
1280 |
| Effective Use of Angiotensin II in Coronavirus Disease 19–Associated Mixed Shock State: A Case Report |
1281 |
| Coronavirus Disease 2019: In-Home Isolation Room Construction |
1282 |
| A Multidisciplinary Team Approach for Triage of Elective Cancer Surgery at the Massachusetts General Hospital During the Novel Coronavirus COVID-19 Outbreak |
1283 |
| The Role of the American Heart Association in the Global COVID-19 Pandemic |
1284 |
| SARS-CoV-2 Infection among Travelers Returning from Wuhan, China |
1285 |
| Managing the Stress of the Covid-19 Pandemic |
1286 |
| COVID19 –Nuclear Medicine Departments, be prepared! |
1287 |
| Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China |
1288 |
| The Role of Viral Coinfection in Bronchiolitis Treated With High-Flow Nasal Cannula at PediatricEmergency Department During 2 Consecutive Seasons An Observational Study |
1289 |
| COVID-19 Continues to Spread |
1290 |
| Rehabilitation following critical illness in people with COVID-19 infection |
1291 |
| coronavirus-19 (COVID-19) |
1292 |
| Incidental CT Findings Suspicious for Covid-19 Associated Pneumonia on Nuclear Medicine Exams: Recognition and Management Plan |
1293 |
| FECAL-ORAL TRANSMISSION OF SARS-COV-2 IN CHILDREN |
1294 |
| Anesthetic Management of Endovascular Treatment of Acute Ischemic Stroke During COVID-19 Pandemic: Consensus Statement from Society for Neuroscience in Anesthesiology & Critical Care (SNACC) |
1295 |
| Transmission of respiratory tract infections at mass gathering events |
1296 |
| Oncologist Urges COVID-19 “Castrated” Live Vaccine Initiative |
1297 |
| coronavirus disease 2019 (COVID-19) |
1298 |
| Managing Resident Workforce and Education During the COVID-19 Pandemic |
1299 |
| Managing Resident Workforce and Education During the COVID-19 Pandemic |
1300 |
| Diseases of the Colon & Rectum Publish Ahead of Print |
1301 |
| Deep Learning Localization of Pneumonia 2019 Coronavirus (COVID-19) Outbreak |
1302 |
| Coinfection of Influenza Virus and Severe Acute RespiratorySyndrome Coronavirus 2(SARS-COV-2) |
1303 |
| Use of HandheldTransceiver for HospitalHealthcare Workers-Caregiver Communication During the Coronavirusdisease 2019 (COVID-19)Outbreak in PediatricEmergency Department |
1304 |
| The explosive epidemic outbreak of novelcoronavirus disease 2019 (COVID-19) and thepersistent threat of respiratory tract infectiousdiseases to global health security |
1305 |
| Brace for Chloroquine PoisoningsBecause of the Coronavirus Pandemic |
1306 |
| Impact of Coronavirus Disease 2019 (COVID-19)Outbreak on ST-Segment–Elevation MyocardialInfarction Care in Hong Kong, China |
1307 |
| Take Precautions |
1308 |
| Coronavirus disease 2019 (COVID-19) |
1309 |
| Renin-Angiotensin System Blockers andthe COVID-19 Pandemic |
1310 |
| Cardiovascular Pharmacology in the Time of COVID-19 |
1311 |
| A Novel Coronavirus Emerging in China — Key Questions for Impact Assessment |
1312 |
| Another Decade, Another Coronavirus |
1313 |
| Importation and Human-to-Human Transmissionof a Novel Coronavirus in Vietnam |
1314 |
| Journey of a Thai Taxi Driver and Novel Coronavirus |
1315 |
| European Society For Emergency Medicine position paper on emergency medical systems response to COVID-19 |
1316 |
| A novel Coronavirus disease (COVID-19) |
1317 |
| The coronavirus disease 2019 (COVID-19) |
1318 |
| COVID-19 pandemic |
1319 |
| coronavirus disease 2019 (COVID-19) |
1320 |
| Challenges for Obstetricians and the Countermeasures of COVID-19 Epidemic |
1321 |
| Consensus on pre-examination and triagein clinic of dermatology during outbreak of COVid 19 from Chinese |
1322 |
| The Impact of the COVID-19 Pandemic on Cancer Patients |
1323 |
| The novel coronavirus disease 2019 (COVID-19) |
1324 |
| Coronavirus Disease 2019 (COVID-19) |
1325 |
| COVID-19: Coronavirus Disease 2019 |
1326 |
| The novel coronavirus SARS-CoV-2 |
1327 |
| infections with the SARS-CoV-2 |
1328 |
| COVID-19 Infection |
1329 |
| Response of Chinese Anesthesiologists to the COVID-19 Outbreak |
1330 |
| COVID-19 Outbreak and Surgical Practice: Unexpected Fatality in Perioperative Period |
1331 |
| novel coronavirus (SARS-CoV-2) |
1332 |
| Early Transmission Dynamics in Wuhan, China,of Novel Coronavirus–Infected Pneumonia |
1333 |
| Recommendations for respiratory rehabilitation in adults with COVID-19 |
1334 |
| Lung transplantation as therapeutic option in acute respiratory distress syndrome for COVID-19-related pulmonary fibrosis |
1335 |
| Distribution of the COVID-19 Epidemic and Correlation with Population Emigration from Wuhan, China |
1336 |
| The outbreak of COVID-19: An overview |
1337 |
| Coronavirus Disease 2019 (COVID-19) |
1338 |
| An Overview of COVID-19 and the Roles of Healthcare Workers |
1339 |
| COVID-19: Financial Stress Test for Academic Medical Centers |
1340 |
| Clinical and High-Resolution CT Features of the COVID-19 Infection: Comparison of the Initial and Follow-up Changes |
1341 |
| Survey of COVID-19 Disease Among Orthopaedic Surgeons in Wuhan, People’s Republic of China |
1342 |
| Characteristics and Early Prognosis of COVID-19 Infection in Fracture Patients |
1343 |
| Risk Stratification and PPE Use in Pediatric Endoscopy During the COVID-19 Outbreak:A Single-Center Protocol |
1344 |
| A Comparative Study of Chest Computed TomographyFeatures in Young and Older Adults With Corona Virus Disease (COVID-19) |
1345 |
| A Diabetic Patient With 2019-nCoV (COVID-19) InfectionWho Recovered and Was Discharged From Hospital |
1346 |
| Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia |
1347 |
| coronavirus-19 (COVID-19) |
1348 |
| Preparing a neurology department for SARS-CoV-2 (COVID-19) |
1349 |
| Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic |
1350 |
| COVID-19 is catalyzing the adoption of teleneurology |
1351 |
| COVID-19 in Children in the United States: Intensive Care Admissions, Estimated Total Infected, and Projected Numbers of Severe Pediatric Cases in 2020 |
1352 |
| Looking ahead: The risk of neurologic complications due to COVID-19 Carlos A. Pérez, MD |
1353 |
Radiation therapy considerations during the COVID-19 Pandemic: Literature review and
expert opinions |
1354 |
Medical genetics education in the midst of the COVID-19
pandemic: Shared resources |
1355 |
| Aerosol or Droplet: Critical Definitions in the COVID-19 Era |
1356 |
| Recommendations for general surgery activitiesin a pandemic scenario (SARS-CoV-2) |
1357 |
| Drug Development and Medicinal Chemistry Efforts Toward SARS-Coronavirus and Covid-19 Therapeutics |
1358 |
| Meeting the Challenge of the 2019 Novel Coronavirus Disease in Patients With Cancer |
1359 |
Incidence of Adverse Drug Reactions in COVID-19 patients in China: an active monitoring
study by Hospital Pharmacovigilance System |
1360 |
| The time is now: Expedited HIV differentiated service delivery during the COVID-19 pandemic |
1361 |
| Lessons learned from HIV can inform our approach to COVID-19 stigma |
1362 |
Does high cardiorespiratory fitness confer some protection against pro-inflammatory responses
after infection by SARS-CoV-2? |
1363 |
| Weight Stigma and the “Quarantine-15” |
1364 |
| Using heparin molecules to manage COVID-2019 |
1365 |
| How should we treat pregnant women infected with SARS-CoV-2? |
1366 |
| Lifestyle behaviours during the COVID-19 – time to connect |
1367 |
Covid-19 pneumonia in a kidney transplant recipient successfully treated with Tocilizumab and
Hydroxychloroquine |
1368 |
| Economic Thoughts on COVID-19 for Canadian Food Processors |
1369 |
| The Impact of COVID-19 on Food Retail and Food Service in Canada: Preliminary Assessment |
1370 |
| The COVID-19 Pandemic: Anticipating its Effects on Canada’s Agricultural Trade |
1371 |
| The need for neurologists in the care of COVID-19 patients |
1372 |
COVID-19 infection and treatment with hydroxychloroquine cause severe
haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency |
1373 |
Priority plan for invasive cardiac electrophysiology procedures during the coronavirus disease 2019
(COVID‐19) pandemic |
1374 |
| Laboratory haemostasis monitoring in COVID-19 |
1375 |
| Lupus anticoagulant is frequent in patients with Covid-19 |
1376 |
| Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy |
1377 |
Management of ST-segment-elevation myocardial infarction during the coronavirus disease 2019 (COVID-19) outbreak: Iranian“247” National Committee's position paper on primary
percutaneous coronary intervention |
1378 |
| Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence |
1379 |
Chloroquine dosing recommendations for pediatric COVID-19 supported by modeling and
simulation |
1380 |
Early Self-Proning in Awake, Non-intubated Patients in the Emergency Department: A Single
ED’s Experience during the COVID-19 Pandemic |
1381 |
| Optimizing psychiatric care during the COVID-19 pandemic |
1382 |
| Solid Organ Transplantation Programs Facing Lack of Empiric Evidence in the COVID-19 Pandemic: A By-proxy Society Recommendation Consensus Approach |
1383 |
| Management of advanced melanoma in the COVID-19 era |
1384 |
| Alopecia areata not due by isotretinoin. A thought in COVID-19 time. |
1385 |
| Integration of telemedicine into the public health response to COVID-19 must include dentists |
1386 |
| Acute-onset smell and taste disorders in the context of Covid-19: a pilot multicenter PCR- based case-control study. Short running title: chemosensory disorders in Covid-19. |
1387 |
| Inpatient care for dermatological patients during SARS- CoV-2 – a case report from Portugal |
1388 |
| Covid-19: Supporting nurses’ psychological and mental health |
1389 |
| Scientific research progress of COVID-19/ SARS-CoV-2 in the first five months |
1390 |
| High incidence of venous thromboembolic events in anticoagulated severe COVID- 19 patients |
1391 |
Management of ST-segment-elevation myocardial infarction during the coronavirus disease 2019 (COVID-19) outbreak: Iranian“247” National Committee's position paper on primary
percutaneous coronary intervention |
1392 |
| Different future |
1393 |
| Infection risk in a gastroenterological ward during a nosocomial COVID-19 infection event |
1394 |
| The emergence of a novel coronavirus (SARS‐CoV-2) disease and their neuroinvasive propensity may affect in COVID‐19 patients |
1395 |
Evaluation of the auxiliary diagnostic value of antibody assays for the detection of novel coronavirus
(SARS-CoV-2) |
1396 |
| Potential of live pathogen vaccines for defeating the COVID- 19 pandemic: history and mechanism |
1397 |
| Decontamination of face masks with steam for mask reuse in fighting the pandemic COVID-19: experimental supports |
1398 |
| Co-detection of respiratory pathogens in patients hospitalized with Coronavirus viral disease-2019 pneumonia |
1399 |
| Response to Char’s comment: Comment on Li et al.: COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis |
1400 |
| How to Perform Pediatric Lung Ultrasound Examinations in the Time of COVID-19 |
1401 |
| MDS-UPDRS use in the COVID era. |
1402 |
| Mesenchymal stem cells as a potential treatment for critically ill patients with coronavirus disease 2019 |
1403 |
| In reply |
1404 |
| Hydatidiform mole in the era of COVID-19 pandemic. Is there an association? |
1405 |
| Thoughts about Public Space During Covid-19 Pandemic |
1406 |
Delivering extracorporeal membrane oxygenation for patients with COVID-19: what, who, when
and how? |
1407 |
| Pandemic cities: Between mimicry and trickery |
1408 |
| Divided in a connected world: Reflections on COVID 19 from Hong Kong |
1409 |
| Reflections on COVID-19 in Sydney, Australia |
1410 |
| Pandemic in Melbourne |
1411 |
| Dermatologists and SARS-CoV-2: The impact of the pandemic on daily practice |
1412 |
| COVID-19 and viral hepatitis elimination programs: Are we stepping backward? |
1413 |
| Managing childhood allergies and immunodeficiencies during respiratory virus epidemics – the 2020 COVID-19 pandemic A statement from the EAACI-Section on Pediatrics |
1414 |
Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but
recover. |
1415 |
SUCCESSFUL CONTAINMENT OF COVID-19 OUTBREAK IN A LARGE MATERNITY AND PERINATAL
CENTER WHILE CONTINUING CLINICAL SERVICE |
1416 |
| Explanation for COVID-19 infection neurological damage and reactivations Explanation for COVID-19 infection reactivations |
1417 |
| Points to consider in the preparation and transfusion of COVID-19 convalescent plasma |
1418 |
| Viruses to fight other viruses: the influenza vaccine case |
1419 |
| Public health, health systems and palliation planning for COVID-19 on an exponential timeline |
1420 |
| COVID-19 and new-onset arrhythmia |
1421 |
| The challenge of managing patients with COVID-19 and acute behavioural disturbances |
1422 |
| The COVID-19 pandemic: some lessons learned about crisis preparedness and management, and the need for international benchmarking to reduce deficits |
1423 |
| The role of occupational dermatology in the COVID-19 outbreak |
1424 |
A Case of SARS-CoV-2-pneumonia with successful antiviral therapy in a 77-year-old male with
heart transplant |
1425 |
| Therapeutic uncertainties in people with cardiometabolic diseases and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19) |
1426 |
| Obesity and SARS-CoV-2: a population to safeguard |
1427 |
| Letter to the Editor: Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab |
1428 |
| Epidemiological trends of COVID-19 epidemic in Italy during March 2020. From 1,000 to 100,000 cases |
1429 |
| Understanding evolution of SARS-CoV-2: a perspective from analysis of genetic diversity of RdRp gene |
1430 |
| CT imaging features of 4,121 patients with COVID-19: a meta-analysis |
1431 |
| Comment on Li et al.: COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis |
1432 |
| Central Nervous System Involvement by Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2) |
1433 |
| Psychological stress of medical staffs during outbreak of COVID-19 and adjustment strategy |
1434 |
| An effective screening and management process in the outpatient clinic for patients requiring hospitalization during the COVID-19 pandemic |
1435 |
| Keep your community safe while COVID-19 spreads globally |
1436 |
| Working from home? Follow these tips for successful remote work |
1437 |
Is Adipose Tissue a Reservoir for Viral Spread, Immune Activation and Cytokine mplification
in COVID-19 |
1438 |
| Targeting the Adipose Tissue in COVID-19 |
1439 |
| Managing a tertiary‐levelNICU in the time ofCOVID‐19: Lessons learned from a high‐risk zone |
1440 |
| Melatonin: Roles in influenza, Covid-19, and other viral infections |
1441 |
| COVID-19 associated coagulopathy and thromboembolic disease: Commentary on an interim expert guidance |
1442 |
| Keep Your Community Safe While COVID-19 Spreads Globally |
1443 |
| Response of a tertiary dermatology department to COVID-19 |
1444 |
| COVID-19 Infection in Patients with Sickle Cell Disease |
1445 |
| COVID-19 in a High-Risk Dual Heart and Kidney Transplant Recipient |
1446 |
| Agriculture, Transportation, and the COVID-19 Crisis |
1447 |
| Labour Issues and COVID-19 |
1448 |
| Food supply chains during the COVID-19 pandemic |
1449 |
| Potential Implications of COVID-19 on the Canadian Pork Industry |
1450 |
| The Impact of COVID-19 on the Grains and Oilseeds Sector |
1451 |
| Economic Thoughts on the Potential Implications of COVID-19 on the Canadian Dairy and Poultry Sectors |
1452 |
| Clinical and Autoimmune Characteristics of Severe and Critical Cases with COVID-19 |
1453 |
| Comment on “Cutaneous manifestations in COVID-19: a first perspective ” by Recalcati S. |
1454 |
| The COVID-19 pandemic progresses across the globe at pace, bringing lockdown of countries and continent |
1455 |
| COVID-19, Postacute Care Preparedness, and Nursing Homes: Flawed Policy in the Fog of War |
1456 |
| PARTICIPANT AND CAREGIVER PERSPECTIVES ON CLINICAL RESEARCH DURING COVID-19 PANDEMIC |
1457 |
| Nursing in uncertain times |
1458 |
| Varicella-like exanthem associated with COVID-19 in an 8-year-old girl: A diagnostic clue? |
1459 |
| Off-Label Therapies for COVID-19—Are We All In This Together? |
1460 |
| Experiences of Patients with Rheumatic Diseases in the US During Early Days of the COVID-19 Pandemic |
1461 |
| Comparing rapid scoring systems in mortality prediction of critical ill patients with novel coronavirus disease |
1462 |
| Why is Coronavirus Disease 2019 not as severe in children?—A look at type 2 alveolar cells |
1463 |
| Strategies for patient with cancer during COVID-19 pandemic |
1464 |
| Intubation boxes for managing the airway in patients with COVID-19 |
1465 |
| PPE and possible routes of airborne spread during the COVID-19 pandemic |
1466 |
| Airborne transmission of severe acute respiratory syndrome coronavirus-2 to healthcare orkers: a narrative review |
1467 |
| A process for daily checks when using anaesthetic machines to ventilate the lungs of COVID-19 patients: the ‘domino switch’ technique |
1468 |
| SARS-CoV-2: A new aetiology for atypical lymphocytes |
1469 |
| Editorial: low population mortality from COVID-19 in countries south of latitude 35 degrees North – supports vitamin D as a factor determining severity |
1470 |
| COVID-19 infection may cause ketosis and ketoacidosis |
1471 |
| Challenges of Covid-19 Pandemic for Dermatology |
1472 |
| Doxycycline, a widely used antibiotic in dermatology with a possible anti-inflammatory action against IL-6 in COVID-19 outbreak. |
1473 |
| COVID-19 and psoriasis : should we fear for patients treated with biologics? |
1474 |
| Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2 |
1475 |
| COVID-19 and the clinical hematology laboratory |
1476 |
| Caregiving at a Physical Distance: Initial Thoughts for COVID-19 and Beyond |
1477 |
| Family violence and COVID-19: Increased vulnerability and reduced options for support |
1478 |
| Elder Abuse in the COVID-19 Era |
1479 |
| Challenges and Responsibilities in Caring for the Most Vulnerable during the COVID-19 Pandemic |
1480 |
| Who speaks for nursing? COVID-19 highlighting gaps in leadership. |
1481 |
| COVID-19 under the SARS Cloud: Mental Health Nursing during the Pandemic in Hong Kong |
1482 |
| Response to 'Inaccurate conclusions by Tang and colleagues' |
1483 |
| Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light-based photochemical treatment |
1484 |
| SARS-CoV-2 infection in beta thalassemia: preliminary data from the Italian experience. |
1485 |
| Chinese Bioethicists Speak Out on Covid-19, and Others Follow |
1486 |
| Scarcity in the Covid-19 Pandemic |
1487 |
| Distinct Viral Clades of SARS-CoV-2: Implications for Modeling of Viral Spread |
1488 |
| Serological tests facilitate identification of asymptomatic SARS-CoV-2 infection in Wuhan, China |
1489 |
| Causes of hypogeusia/hyposmia in SARS-CoV2 infected patients |
1490 |
| Serological tests facilitate identification of asymptomatic SARS-CoV-2 infection in Wuhan, China |
1491 |
| Description of COVID-19 cases along with the measures taken on prevention and control in Zhejiang, China |
1492 |
| Positive result of Sars-Cov-2 in faeces and sputum from discharged patient with COVID-19 in Yiwu, China |
1493 |
| Management challenges for chronic dysimmune neuropathies during the COVID-19 pandemic |
1494 |
| World economic prospects monthly overview: world GDP now seen family 2.8% in 2020 |
1495 |
| COVID-19 diagnosis does not rule out other concomitant diseases. |
1496 |
| Extensive hard palate hyperpigmentation associated with chloroquine use |
1497 |
| School leadership in unpredictable times |
1498 |
| Children may be less affected than adults by novel coronavirus (COVID-19) |
1499 |
| Tele(oral)medicine: a new approach during the COVID-19 crisis |
1500 |
| Our Education, Our Concerns: Medical Student Education Impact due to COVID-19 |
1501 |
| SARS-CoV-2: What Can Saliva Tell Us? |
1502 |
| Nursing research is coronavirus research |
1503 |
| Strength, Weakness, Opportunity, Threat (SWOT) Analysis of the Adaptations to Anatomical Education in the United Kingdom and Republic of Ireland in Response to the COIVD-19 Pandemic. |
1504 |
| Coronavirus and diabetes: an update |
1505 |
| COVID-19 and spinal cord injuries: the viewpoint from an emergency department resident with quadriplegia |
1506 |
| Angiotensin-converting enzyme 2 in severe acute respiratory syndrome coronavirus and SARS-CoV-2: A double-edged sword? |
1507 |
| How effective response to COVID‐19 relies on nursing research |
1508 |
| CORONAVIRUS-DAYS IN DERMATOLOGY |
1509 |
| Influenza response planning for the centers of excellence for influenza research and surveillance: Science preparedness for enhancing global health security |
1510 |
| Cardiac involvement in COVID‐19 patients: Risk factors, predictors, and complications: A review |
1511 |
| Coronaviruses and people with intellectual disability: An exploratory data analysis |
1512 |
| Cardiovascular surgery in the COVID‐19 pandemic |
1513 |
| Potential implications of COVID-19 in non-alcoholic fatty liver disease |
1514 |
| D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19 |
1515 |
| Strategies for Prevention of Coronavirus Disease 2019 in the Dental Field |
1516 |
| The outbreak of Novel Coronavirus disease (COVID-19) caused a worrying delay in the diagnosis of oral cancer in north-west Italy: the Turin Metropolitan Area experience. |
1517 |
| Paediatric Anaesthetic implications of COVID-19 – A Review of Current Literature |
1518 |
| Caring for Patients with Advanced Stage Cancer at the Time of COVID-19 |
1519 |
| Supporting pandemic response using genomics and bioinformatics: a case study on the emergent SARS-CoV-2 outbreak |
1520 |
| News briefs |
1521 |
| Surge capacity of intensive care units in case of acute increase in demand caused by COVID-19 in Australia |
1522 |
| COVID-19: A Resident’s Perspective |
1523 |
| Forced Disruption of Anatomy Education in Australia and New Zealand: An Acute Response to the Covid-19 Pandemic |
1524 |
| The Contact Activation System as a Potential Therapeutic Target in Patients with COVID-19 |
1525 |
| Progress and Concept for COVID-19 Vaccine Development |
1526 |
| Advanced forecasting of SARS-CoV-2 related deaths in Italy, Germany, Spain, and New York State |
1527 |
| Why we should not stop giving aspirin to pregnant women during the COVID-19 pandemic |
1528 |
| Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action |
1529 |
| Telemedicine and support groups in order to improve the adherence to treatment and health related quality of life in patients affected by inflammatory skin conditions during COVID-19 emergency |
1530 |
| A novel clinical set up for examining healthy dermatology outpatients in time of Covid-19 |
